| Excerpt | Reference |
|---|
| "A female patient with chronic myelocytic leukemia (CML) in chronic phase after busulfan and interferon treatment had four different cell lines in her bone marrow." | ( Casali, M; Di Raimondo, F; Maserati, E; Milone, G; Parrinello, G; Pasquali, F; Truglio, F, 1992) |
| "Two patients with hematologic relapse of chronic myelogenous leukemia (CML) following allogeneic BMT were treated by abrupt discontinuation of cyclosporine." | ( Bennett, M; Collins, RH; Fay, JW; Kumar, V; Nikein, A; Rogers, ZR, 1992) |
| "A 47-year-old woman with chronic myelogenous leukemia was treated with daily busulfan (total dose approximately 500 mg) from December 1988 to January 1990." | ( Akagawa, S; Aoki, N; Ishikawa, M; Kumagai, T; Matsubara, O; Miyake, S; Ohdama, S; Takano, S; Umino, T, 1992) |
| "One hundred fifteen patients with chronic myelocytic leukemia (CML) were administered busulphan 4 mg/kg for 4 days and cyclophosphamide 60 mg/kg on each of 2 days (BuCy2) followed by allogeneic bone marrow transplantation from histocompatible sibling donors." | ( Atkinson, K; Avalos, B; Biggs, JC; Concannon, AJ; Crilley, P; Dodds, A; Downs, K; Kapoor, N; Szer, J; Tutschka, P, 1992) |
| "Ten cases of chronic myelocytic leukemia (CML) were first treated with ubenimex and cytostatics, then with ubenimex only." | ( Im, T; Nakao, H; Oohira, H; Ota, K; Sannomiya, Y; Sasaki, A; Tatsumi, N; Yasui, Y, 1991) |
| "A patient with chronic myelogenous leukemia (CML) in lymphoid blast crisis developed acute tumor lysis syndrome following administration of high-dose busulfan, cyclophosphamide and cytarabine (Ara-C) in preparation for allogeneic bone marrow transplantation." | ( Gonzales-Chambers, R; Przepiorka, D, 1990) |
| "A 29-year-old man with chronic myeloid leukemia and two successfully treated blast crises exhibited ocular symptoms." | ( Haen, M; Horny, HP; Pleyer, U; Richter, U; Thiel, HJ; Weidle, EG, 1990) |
| "A 61-year-old male was diagnosed as chronic myelocytic leukemia (CML) in 1985 and had been treated with busulfan for 4 years and 5 months (total 3,572 mg)." | ( Hashimoto, M; Hirose, S; Ishikawa, M; Kobayashi, S; Wakabayashi, Y, 1990) |
| "In six patients with untreated, chronic myelocytic leukemia (CML), the dominating thymidine kinase (TK) activity was compared with the fetal form, TK 1, from mitogen stimulated and the adult form TK 2 from unstimulated normal human lymphocytes, and with TK-1-onc, TK-3-onc and TK-4-onc." | ( Munch-Petersen, B, 1990) |
| "Six children with juvenile chronic myelocytic leukemia (JCML) with adverse prognostic features were treated with intensive combination chemotherapy similar to that utilized in patients with acute nonlymphocytic leukemia (ANLL)." | ( Festa, RS; Lanzkowsky, P; Shende, A, 1990) |
| "Treatment of the myeloid blast phase of chronic granulocytic leukemia is still a major problem in clinical hematology." | ( Goudsmit, R; Ho, AD; Hunstein, W; Trümper, LH; van der Lelie, H, 1989) |
| "Ph1-positive chronic myelocytic leukemia (CML) developing in a treated case of acute promyelocytic leukemia (APL) is reported." | ( Maruyama, Y; Nagata, K; Nakamura, S; Onozawa, Y; Sakamaki, H; Yahara, Y, 1989) |
| "To prolong the survival of patients with chronic myeloid leukemia (CML), 19 patients were treated with busulfan to keep their leukocyte counts within normal range by controlling bone marrow hyperplasia." | ( Atogami, S; Itoyama, T; Jinnai, I; Jubashi, T; Kohno, T; Kuriyama, K; Matsuo, T; Nonaka, H; Tomonaga, M; Tsukasaki, K, 1989) |
| "A 4-year-old girl with juvenile chronic myeloid leukemia relapsed after an allogeneic bone marrow transplantation (BMT) and became refractory to conventional chemotherapy." | ( Bashara, S; Goshen, Y; Kaplinsky, C; Stark, B; Yaniv, I; Zaizov, R, 1988) |
| "Fourteen consecutive patients with chronic myelogenous leukemia (CML) blast crisis were treated with a more dose-intensive regimen of daunorubicin (70 mg/m2 per day on days 1-3) and cytosine arabinoside (200 mg/m2 per day as continuous infusion on days 1-9) than usually used in de novo acute myelogenous leukemia." | ( Kouides, PA; Rowe, JM, 1995) |
| "A group of 46 patients with chronic myelogenous leukemia (CML) [chronic phase (CP), 24 patients; accelerated phase (AP), 22 patients] ineligible for allogeneic bone marrow transplantation were given an intensive chemotherapy regimen consisting of idarubicin, intermediate-dose cytarabine, and etoposide." | ( Carella, AM; Ferrero, R; Frassoni, F; Podestá, M; Pollicardo, N; Pungolino, E; Soracco, M, 1994) |
| "Juvenile chronic myelogenous leukemia (CML) is a rare myeloproliferative disease of infants and young children for which there is no effective therapy other than allogeneic bone marrow transplantation." | ( Byrd, RL; Castleberry, RP; Chaffee, S; Cohn, S; Emanuel, PD; Gualtieri, RJ; Homans, A; Nitschke, R; Strauss, L; Zuckerman, KS, 1994) |
| "The cobalamin metabolism in chronic myelogenous leukemia (CML) was evaluated in 18 newly diagnosed and untreated patients by formiminoglutamic acid (FiGlu) and methyl malonic acid excretion (MMA) tests." | ( Gimsing, P; Hippe, E, 1995) |
| "A 13 year old girl diagnosed as having chronic myeloid leukemia (CML) was treated with interferon-alpha (IFN-alpha) alone and 4 months later hematological remission was obtained." | ( Hisakawa, H; Kurashige, T; Okada, T; Tomoda, T; Wakiguchi, H, 1995) |
| "Forty-eight patients with chronic myeloid leukemia (CML) in chronic phase (CP) were treated by autologous stem cells transplantation (ASCT) and alpha Interferon (IFN) with three approaches: 1) ASCT at diagnosis followed by IFN, 2) ASCT post IFN with cells collected after an interval from IFN discontinuance, followed by IFN, 3) ASCT in patients selected by cytoconversion obtained with IFN, performed soon after IFN discontinuance." | ( Alimena, G; Cedrone, M; de Cuia, MR; Lo Coco, F; Mancini, M; Meloni, G; Montefusco, E; Nanni, M; Pinto, R; Rondinelli, MB, 1993) |
| "Twenty-seven patients with chronic myelogenous leukemia (CML)--17 in the chronic phase and 10 in the accelerated phase--were treated with an intensive chemotherapy regimen consisting of idarubicin, arabinosylcytosine, and etoposide." | ( Benvenuto, F; Carella, AM; Ferrero, R; Figari, O; Frassoni, F; Giordano, D; Podestà, M; Pollicardo, N; Pungolino, E; Raffo, MR, 1993) |
| "Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous transplantation using marrow treated ex vivo with mafosfamide." | ( Almici, C; Caramatti, C; Carlo-Stella, C; Cottafavi, L; Dotti, GP; Mangoni, L; Rizzoli, V, 1994) |
| "The blast crisis of chronic myelogenous leukemia (CML) is refractory to most forms of cancer chemotherapy, but may be amenable to drugs that differentiate rather than kill leukemic cells." | ( Choudhury, S; Hait, WN; Murren, JR; Srimatkandada, S, 1993) |
| "Thirty-four patients with chronic myelogenous leukemia in chronic phase were treated with busulfan 16 mg/kg and cyclophosphamide 120 or 200 mg/kg before allogeneic bone marrow transplantation from an HLA-identical sibling." | ( Angelucci, E; Baronciani, D; Erer, B; Galimberti, M; Gaziev, D; Giardini, C; Lucarelli, G; Polchi, P; Rapa, S; Ripalti, M, 1994) |
| "Treatment of a 74 year old patient with chronic myelogenous leukemia (CML) with busulphan resulted in an abrupt and pronounced decrease of the white blood cell (WBC) count with restoration of normal peripheral blood cell morphology and regression of splenomegaly." | ( Fibach, E; Michaeli, J; Rachmilewitz, EA, 1993) |
| "New developments in relation to chronic myelogenous leukemia (CML) are characterized by progress in knowledge of pathogenesis, diagnostic improvement such as nosology of Philadelphia-negative CML and diagnosis of minimal residual disease by molecular techniques, advances in drug therapy with hydroxyurea or interferon alpha, and progress in bone marrow transplantation through availability of unrelated donors." | ( Hehlmann, R, 1994) |
| "Ten adult patients with Ph-positive chronic myelogenous leukemia (CML) received autologous bone marrow transplantation (ABMT) using marrow treated ex vivo with mafosfamide." | ( Almici, C; Caramatti, C; Carlo-Stella, C; Dotti, GP; Mangoni, L; Rizzoli, V, 1993) |
| "None of the patients with chronic myeloid leukemia in blast crisis (n = 12) or with acute lymphocytic leukemia (n = 4) or acute myeloid leukemia (AML) (n = 15) achieved complete remission (CR), although all patients with AML entered on this trial had prior complete remissions that were less than 1 year in duration, and many were refractory, either to primary therapy or to the most recent attempt to obtain CR." | ( Carter, C; Hodges, S; Lee, EJ; Reck, K; Schiffer, CA, 1993) |
| "We proposed a new approach to treat chronic myelogenous leukemia using a combination of busulfan and Bestatin." | ( Saito, Y; Uzuka, Y, 1993) |
| "Thirty patients with chronic myeloid leukemia in chronic phase and less than 1 year from diagnosis were treated with a combination of interferon alfa-2a (IFN) 9 million units daily continuously and intermittent low-dose cytosine arabinoside (Ara-C) 20 mg/m2 daily for 21 days every 42 days." | ( Arthur, CK; Ma, DD, 1993) |
| "Twenty-three patients with chronic myelogenous leukemia in early chronic phase (ECP) and not previously treated with alpha-interferon (IFN-alpha) (10 patients), in ECP but pretreated with IFN-alpha (<12 months) (seven patients) and in late chronic phase (LCP) pretreated with IFN-alpha (>12 months) (six patients) underwent autografting with Philadelphia (Ph) chromosome-negative blood progenitor cells (BPCs) (20 patients), or partially/totally Ph-positive BPCs (three patients), previously mobilized during the early phase of recovery after aplasia induced by intensive chemotherapy." | ( Benvenuto, F; Carella, AM; Carlier, P; Chimirri, F; Dejana, A; Ferrara, RA; Florio, G; Frassoni, F; Gatti, AM; Incagliato, M; Lerma, E; Piaggio, G; Pitto, A; Podestà, M; Pollicardo, N; Prencipe, E; Soracco, M; Valbonesi, M; Vassallo, F; Vimercati, R, 1996) |
| "In 1994, the Italian and the German Chronic myeloid leukemia (CML) trials comparing interferon-alpha (IFN-alpha) with conventional chemotherapy were published." | ( Anseri, H; Baccarani, M; Hasford, J; Hehlmann, R; Tura, S; Zuffa, E, 1996) |
| "One hundred and fifty-nine patients with chronic myelogenous leukemia have been treated in six studies during 10 years at Hannover Medical School University Center." | ( Balleisen, L; Diedrich, H; Fonatsch, C; Freund, M; Grote-Metke, A; Heussner, P; Hild, F; Hinrichs, HF; Kleine, HD; Koch, O; Link, H; Meran, J; Nowak, R; Otremba, B; Poliwoda, H; von Wussow, P, 1996) |
| "Previously untreated patients with chronic myelogenous leukemia were randomly assigned to receive either hydroxyurea (50 mg per kilogram of body weight per day) and interferon alfa-2b (5 million units per square meter of body-surface area per day), or hydroxyurea and interferon in the same dosages plus monthly courses of cytarabine (20 mg per square meter per day, for 10 days)." | ( Abgrall, JF; Bouabdallah, R; Chastang, C; Cheron, N; Guerci, A; Guilhot, F; Guyotat, D; Harousseau, JL; Maloisel, F; Michallet, M; Nicolini, F; Tanzer, J, 1997) |
| "Recently we observed a case of chronic myeloid leukemia (CML) with t(9;22) after therapy of a germ cell tumor with etoposide, cisplatin and bleomycin." | ( Brøndum-Nielsen, K; Johansson, B; Karle, H; Pedersen-Bjergaard, J, 1997) |
| "A 48-year-old woman was admitted with chronic myelogenous leukemia in November, 1996 and was treated with hydroxyurea (HU), because of marked leukocytosis; WBC 404,000/microliter." | ( Fujimaki, K; Fujisawa, S; Hattori, M; Kodama, F; Maruta, A; Mohri, H; Motomura, S; Okubo, T; Sakai, R; Takahashi, N; Tomita, N, 1998) |
| "Transformed chronic myeloid leukemia (CML) has a dismal prognosis, and treatment with a variety of chemotherapeutic agents is extremely disappointing." | ( Heinemann, V; Jehn, U, 1998) |
| "A 36-year-old man suffering from chronic myeloid leukemia (in chronic phase) was initially treated with busulphan." | ( Kochupillai, V; Pati, HP; Sharma, S, 1998) |
| "A patient with chronic myelogenous leukemia who developed arthritis secondary to IFN therapy is presented." | ( Nesher, G; Ruchlemer, R, 1998) |
| "The authors describe two patients with chronic myeloid leukemia treated with IFN-alpha following high dose chemotherapy who developed renal failure and proteinuria after 3 and 4 weeks of IFN-alpha therapy, respectively." | ( Baer, MR; Herzig, GP; Jenis, EH; Mookerjee, BK; Schriber, JR; Shah, M; Wetzler, M, 1998) |
| "Three patients with chronic myeloid leukemia (CML) in blastic transformation were treated with G-CSF plus middle dose cytosine arabinoside (Ara-C)." | ( Hayashi, S; Inatomi, Y; Iwama, H; Katagiri, T; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Nehashi, Y; Ohyashiki, K; Shimamoto, T; Shyohji, N; Toyama, K; Uchida, Y; Yaguchi, M, 1998) |
| "The prognosis of blast crisis (BC) of chronic myelogenous leukemia (CML) is extremely poor despite many efforts to induce remission with chemotherapy." | ( Chiba, S; Hirai, H; Honda, H; Kanda, Y; Yazaki, Y, 1999) |
| "We describe a patient with chronic myeloid leukemia on interferon treatment, who developed BMN with symptoms and signs masquerading as interferon toxicity." | ( Chim, CS; Lam, CK; Ma, SK, 1999) |
| "We describe a patient with chronic myelogenous leukemia (CML) and a patient with hairy cell leukemia being effectively treated with alpha-interferon who developed a seropositive chronic polyarthritis formally fulfilling the ACR criteria for rheumatoid arthritis." | ( Einsele, H; Kanz, L; Kötter, I; Mohren, M; Müller, CA, 1999) |
| "We report here a very rare case of chronic myeloid leukemia (CML) with a minor bcr-abl transcript, which developed following long-term chemotherapy with fluorouracil for esophageal carcinoma." | ( Dan, K; Hanawa, H; Inokuchi, K; Nakamura, H; Tajika, K; Tamura, H; Yamaguchi, H, 2000) |
| "Its association with chronic myelogenous leukemia (CML) is extremely rare, and typical manifestations of BD were observed in a very few patients with CML, mainly under interferon-alpha (IFN-alpha) treatment." | ( Loukopoulos, D; Nodaros, K; Rombos, J; Terpos, E; Vaiopoulos, G; Viniou, N, 2001) |
| "The treatment recommendations for chronic myelogenous leukemia (CML) are evolving rapidly." | ( Baccarani, M; Capdeville, R; Druker, BJ; Ford, JM; Goldman, JM; Sawyers, CL, 2001) |
| "A 9-year-old boy with secondary chronic myelogenous leukemia after treatment of acute lymphoblastic leukemia underwent allogeneic bone marrow transplantation (BMT) from an HLA-identical sibling in December 1998." | ( Hojo, H; Ito, M; Kikuta, A; Nemoto, K; Ohto, H; Sano, H, 2002) |
| "Philadelphia chromosome-positive chronic myelogenous leukemia (CML) is a rare disease in children, and the optimal therapy is not clearly defined in these patients when a human leukocyte antigen-identical donor is not available." | ( Boccara, JF; Brice, P; Demeoq, F; Guilhot, F; Guilhot, J; Guyotat, D; Millot, F; Philippe, N; Thyss, A; Vilque, JP; Wetterwald, M, 2002) |
| "We report a case of chronic myelogenous leukemia (CML) in which the bone marrow achieved cytogenetic complete remission (CCR) achieved by treatment with interferon-alpha and oral cytarabine ocfosfate after extramedullary blast crisis." | ( Gotoh, A; Kawakubo, K; Kuriyama, Y; Miyazawa, K; Ohyashiki, K; Sashida, G; Uchida, Y, 2002) |
| "Chronic phase chronic myelogenous leukemia patients treated with STI571 have durable responses; however, most responding blast phase patients relapse despite continued therapy." | ( Buchdunger, E; Corbin, AS; Druker, BJ; Pascal, F, 2002) |
| "The therapy of chronic myeloid leukemia (CML), characterized by the presence of the Philadelphia chromosome in the clonal hematopoietic stem cells, has changed dramatically in the last year with the development of a specific inhibitor of the BCR-ABL tyrosine kinase." | ( Cáceres, W; Corujo, Y, 2002) |
| "Fourteen patients with blastic phase chronic myelogenous leukemia received combination chemotherapy with mitoxantrone 5 mg/m2 intravenously daily for 3 days, cytosine arabinoside 100 mg/m2 intravenously over 2 hours bid for 7 days and high dose methylprednisolone 1000 mg/day intravenously for 5 days." | ( Ayyildiz, O; Bolaman, Z; Demir, S; Kadiköylü, G; Köseoğlu, M; Müftüoğlu, E; Sönmez, HM, 2002) |
| "A 73-year-old woman with chronic myeloid leukemia was treated with interferon-alpha, hydroxyurea, and busulfan before imatinib mesylate treatment." | ( Ito, Y; Nakajima, A; Ohyashiki, K; Shimamoto, T; Sshida, G; Sumi, M; Tauchi, T, 2002) |
| "The treatment options for chronic myelogenous leukemia (CML) continue to evolve rapidly." | ( Cortes, J; Druker, BJ; O'Brien, SG; Radich, J, 2002) |
| "We treated two chronic phase chronic myelogenous leukemia patients with imatinib mesylate." | ( Akiyama, T; Fujimi, A; Kato, J; Kikuchi, T; Kogawa, K; Kura, T; Maeda, T; Matsunaga, T; Niitsu, Y; Sato, T; Seki, R; Takahari, D; Takemoto, N; Tanaka, I; Terui, T, 2002) |
| "The prognosis of patients with chronic myeloid leukemia in blastic crisis (CML-BC) remains extremely poor, and multiagent chemotherapy regimens commonly used to treat acute leukemia offer only short-term benefits." | ( Hirose, Y; Ito, M; Iwai, M; Kiyoi, H; Naoe, T; Yokozawa, T, 2002) |
| "Imatinib-treated chronic myeloid leukemia (CML) patients with acquired resistance commonly have detectable BCR-ABL kinase domain mutations." | ( Arthur, C; Branford, S; Grigg, A; Herrmann, R; Hughes, T; Joske, D; Lynch, K; Parkinson, I; Rudzki, Z; Seymour, JF; Szer, J; Taylor, K; Walsh, S, 2003) |
| "The therapy of chronic myeloid leukemia, characterized by the presence of the Philadelphia chromosome in the clonal hematopoietic stem cells, has changed dramatically in the last years with the development of a specific inhibitor of the BCR-ABL tyrosine kinase: tyrosine kinase inhibitor imatinib mesylate (formerly STI571, [Glivec])." | ( Bossone, G; Della Longa, G; Di Cocco, B; Salesi, N, 2003) |
| "A 58-year-old woman with chronic myeloid leukemia (CML), and previous intolerance to interferon was treated with the BCR-ABL tyrosine kinase protein inhibitor imatinib mesylate." | ( Botey, A; Cervantes, F; Pou, M; Saurina, A; Saval, N; Solé, M; Vera, M, 2003) |
| "A 60-year-old white woman with chronic myeloid leukemia who had been treated with hydroxyurea for 7 years was offered anagrelide to control thrombocytosis." | ( Brink, DJ; Mazer, MA; Raghavan, M, 2003) |
| "We describe a patient with chronic myelogenous leukemia (CML) who developed extramedullary blast crisis, and was successfully treated with imatinib mesylate (STI571)." | ( Ikeda, Y; Miyazaki, K; Mori, T; Naito, K; Okamoto, S; Tsukada, Y, 2003) |
| "We report a chronic myeloid leukemia (CML) patient in chronic phase (CP) who developed blast crisis (BC) under imatinib mesylate administered in a dose reduced and non-continuous fashion because of hematologic intolerance." | ( Brezinschek, R; Linkesch, W; Neumeister, P; Sill, H; Staber, PB, 2003) |
| "A 5-year-old girl with Ph-positive chronic myelogenous leukemia, who underwent umbilical cord blood transplantation, developed two episodes of electrical status epilepticus while receiving tacrolimus (FK506) then cyclosporin A (CsA), as treatment against graft-versus-host disease." | ( Mori, T; Shimada, H; Takahashi, T; Takeoka, M; Yoshida, Y; Yoshihara, H, 2003) |
| "A significant proportion of chronic myeloid leukemia (CML) patients achieve a major cytogenetic remission (MCR) to imatinib therapy after failing interferon (IFN) alpha-based protocols." | ( Berger, U; Gschaidmeier, H; Hehlmann, R; Hochhaus, A; König, H; Kreil, S; Lahaye, T; Merx, K; Müller, MC; Paschka, P; Petzold, A; Schoch, C; Weisser, A, 2003) |
| "We treated 12 patients with chronic myelogenous leukemia (CML) with a low-intensity preparative regimen followed by allogeneic stem cell transplantation in an attempt to confer a curative graft-versus-leukemia (GVL) effect with minimum morbidity." | ( Barrett, AJ; Childs, RW; Greene, A; Sloand, E; Solomon, S; Young, NS, 2003) |
| "A 6-year-old girl with chronic myeloid leukemia (CML) was treated with imatinib 230 mg/m2/day and its pharmacokinetics were investigated." | ( Chida, S; Endo, M; Hosokawa, T; Nakatuji, Y; Sugawara, W, 2003) |
| "A 71-year-old man with chronic myelogenous leukemia received interferon therapy for 21 months, but did not have complete cytogenetic response." | ( Ajima, A; Hasegawa, Y; Kojima, H; Nagasawa, T; Takayama, N, 2003) |
| "To study the possibility of curing chronic myeloid leukemia with autogeneic hemopoietic stem cell transplantation in patients with negative Philadelphia (Ph) chromosome induced by imatinib mesylate (STI 571) treatment." | ( Liu, QF; Liu, XL; Meng, FY; Song, LL; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhou, SY, 2003) |
| "Two patients with chronic myeloid leukemia in chronic phase, who had 90% Ph chromosome-positive cells and bcr/abl fusion gene-positive cells as shown by interphase fluorescence in situ hybridization (I-FISH), failed to respond favorably to interferon-alpha therapy in the treatment courses of 7 and 8 months, respectively." | ( Liu, QF; Liu, XL; Meng, FY; Song, LL; Sun, J; Xu, B; Xu, D; Yang, LJ; Zhou, SY, 2003) |
| "Moreover, patients with chronic myeloid leukemia (CML) who were in complete cytogenetic or molecular response after imatinib treatment restored their blood PDCs both quantitatively and functionally comparable to healthy donors, in contrast to patients not responding to imatinib, further confirming that disease response to imatinib is accompanied by restoration of PDC function in vivo." | ( Blaise, D; Damaj, G; Gaugler, B; Isnardon, D; Jourdan, E; Mami, NB; Mohty, M; Olive, D; Vey, N, 2004) |
| "This drug has had a major impact on the treatment of chronic myelogenous leukemia (CML) as well as other blood neoplasias and solid tumors with etiologies based on activation of these tyrosine kinases." | ( Witte, ON; Wong, S, 2004) |
| "We report a case of chronic myeloid leukemia (CML) with clonal Philadelphia negative hematopoiesis arising after treatment with imatinib." | ( Fukuhara, S; Ishii, K; Nomura, S; Yamamoto, Y, 2004) |
| "Patients with chronic myeloid leukemia now have several potential treatment options from which to choose." | ( Angstreich, GR; Jones, RJ; Smith, BD, 2004) |
| "Treatment of chronic myelogenous leukemia (CML) has been greatly enhanced by the development of Imatinib mesylate, a specific inhibitor of the BCR/ABL tyrosine kinase." | ( Bhatia, R; Holtz, MS, 2004) |
| "Monotherapy of chronic myeloid leukemia (CML) with imatinib mesylate has been cast into shadow by the evolution of clinical resistance during therapy." | ( Baluch, S; Barnes, DJ; Bornmann, WG; Clarkson, BM; Goldman, JM; Mahon, FX; Melo, JV; Tipping, AJ; Veach, DR, 2004) |
| "A 65-year-old man was diagnosed with chronic myeloid leukemia (CML) in February 1990, and was treated with busulfan and ubenimex." | ( Fujimaki, K; Ishigatsubo, Y; Kanamori, H; Koharazawa, H; Taguchi, J; Takabayashi, M; Takasaki, H; Yamaji, S, 2004) |
| "We studied 94 clinically heterogeneous chronic myeloid leukemia (CML) patients and found that the duration of treatment with interferon-alpha (IFN-alpha) prior to imatinib therapy may not improve response to imatinib for patients in chronic phase but a shorter period between CML diagnosis and the initiation of imatinib is predictive for a better molecular response to therapy (p<0." | ( Darré, S; Facon, T; Guilhot, J; Laï, JL; Preudhomme, C; Roche-Lestienne, C, 2005) |
| "We describe a method for monitoring chronic myeloid leukemia (CML) patients treated with imatinib that uses fluorescence in situ hybridization (FISH) to detect BCR-ABL in peripheral blood (PB) granulocytes." | ( Decoteau, J; Hirokawa, M; Ichinohasama, R; Kawabata, Y; Kitabayashi, A; Kobayashi, Y; Kume, M; Miura, AB; Miura, I; Nishijima, H; Ohtsubo, K; Otane, W; Sawada, K; Takahashi, K; Takahashi, N; Yoshioka, T, 2005) |
| "We report on a patient with chronic myeloid leukemia (CML) undergoing acceleration during imatinib treatment." | ( Büsche, G; Gadzicki, D; Just, M; Kreipe, H; Schlegelberger, B; Steinemann, D; von Neuhoff, N; Wilkens, L, 2005) |
| "Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60 percent of cases." | ( Biondi, A; Colnaghi, F; Dassi, M; Elli, E; Fumagalli, M; Gambacorti-Passerini, C; Giudici, G; Parma, M; Perseghin, P; Pioltelli, P; Pogliani, EM; Ponchio, L; Tornaghi, L, 2005) |
| "The treatment of chronic myeloid leukemia has changed dramatically in the last few years." | ( Cortes, J; Kantarjian, H, 2005) |
| "In the era of molecular therapy of chronic myelogenous leukemia (CML) applying BCR-ABL tyrosine kinase inhibitors, the usefulness of molecular end points, in particular, quantitative polymerase chain reaction (PCR) for BCR-ABL in monitoring responses has been broadly accepted." | ( Bornhäuser, M; Bunjes, D; Fischer, T; Gschaidmeier, H; Haus, U; Hess, G; Hochhaus, A; Huber, C; Kindler, T; Kobbe, G; Ledderose, G; Schwerdtfeger, R; Siegert, W; Ullmann, AJ; Wassmann, B, 2005) |
| "Treatment of chronic myeloid leukemia (CML) patients using imatinib alone is unlikely to be curative." | ( Hughes, TP; Hui, CH, 2003) |
| "The treatment of chronic myeloid leukemia (CML) has been revolutionized by the small molecule BCR-ABL-selective kinase inhibitor imatinib." | ( Shah, NP, 2005) |
| "Patients with chronic myeloid leukemia (CML) treated with imatinib in early chronic phase tend to have durable remissions, but there is a high rate of relapse in patients with advanced disease." | ( Deininger, MW; Lange, T; Park, B; Willis, SG, 2005) |
| "Imatinib-refractory chronic myelogenous leukemia (CML) patients can experience long-term disease-free survival with myeloablative therapy and allogeneic hematopoietic cell transplantation; however, associated complications carry a significant risk of mortality." | ( Andersson, BS; Champlin, RE; de Lima, M; Decker, WK; Eaves, AC; Eaves, C; Jones, R; Lee, MS; Li, S; McMannis, JD; Ng, J; Niu, T; Robinson, SN; Shpall, EJ; Xing, D; Yang, H; Yao, X, 2006) |
| "The records of all patients with chronic myeloid leukemia (CML) treated with imatinib were reviewed." | ( Ault, P; Beran, M; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Rios, MB; Talpaz, M, 2006) |
| "Although most patients with chronic myeloid leukemia (CML) treated with imatinib mesylate achieve a complete cytogenetic response (CCR), some patients will relapse." | ( Deininger, MW; Druker, BJ; Love, Z; Mauro, MJ; Mongoue-Tchokote, S; Mori, M; Press, RD; Tran, T; Tronnes, AA; Yang, R, 2006) |
| "She was under hydroxyurea treatment for chronic myeloid leukemia at the time." | ( Kovalev, J; Lurie, M; Munichor, M; Rosner, I; Slobodin, G, 2006) |
| "At diagnosis, chronic myeloid leukemia patients had abnormally high serum levels of sMICA and weak NKG2D expression on NK and CD8+ T cells, which were restored by imatinib mesylate (IM) therapy." | ( Boissel, N; Brun, M; Cayuela, JM; Charron, D; Dombret, H; Dulphy, N; Le Bouteiller, P; Mahon, FX; Rea, D; Rousselot, P; Steinle, A; Tamouza, R; Tieng, V; Toubert, A, 2006) |
| "Imatinib mesylate (IM) therapy for chronic myeloid leukemia (CML) has transformed the treatment of this disease." | ( Holyoake, TL; Jordanides, NE; Jorgensen, HG; Mountford, JC, 2006) |
| "Imatinib mesylate, licensed to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, is metabolized by means of cytochrome P450 3A and excreted primarily in the bile." | ( Beumer, JH; Egorin, MJ; Lagattuta, TF; Natale, JJ; Raptis, A, 2006) |
| "In the therapy of chronic myelogenous leukemia (CML), interferon (IFN) brought about a big progress resulting in the good hematologic as well as cytogenetic response and prolongation of survival." | ( Urabe, A, 2006) |
| "Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitor imatinib represents a successful application of molecularly targeted cancer therapy." | ( Glauche, I; Hochhaus, A; Horn, M; Loeffler, M; Mueller, MC; Roeder, I, 2006) |
| "We have previously reported that human chronic myeloid leukemia (CML) KU812 and K562 cells show inhibited cellular proliferation in response to treatment with activin A, a member of TGF-beta superfamily." | ( Fukuchi, Y; Ikeda, Y; Kawamura, C; Kizaki, M; Yamato, K, 2006) |
| "Treatment options for chronic myeloid leukemia (CML) are discussed." | ( Frame, D, 2006) |
| "Most patients with a chronic phase of chronic myeloid leukemia (CML) treated with imatinib mesylate achieve a cytogenetic remission, but in the majority, residual disease is detectable by RT-PCR." | ( Hullberg, S; Ricksten, A; Stockelberg, D; Wadenvik, H; Wei, Y, 2007) |
| "Treatment of chronic myelogenous leukemia-derived cell lines with As(2)O(3) also results in phosphorylation of the 4E-BP1 repressor of mRNA translation on Thr(37)/Thr(46) and Thr(70), sites required for its deactivation and its dissociation from the eukaryotic initiation factor 4E complex to allow cap-dependent mRNA translation." | ( Altman, J; Giafis, N; Katsoulidis, E; Mears, H; Platanias, LC; Redig, AJ; Sassano, A; Smith, J; Tallman, MS; Yoon, P, 2006) |
| "The success of imatinib therapy for chronic myeloid leukemia (CML) has brought new challenges; these include optimizing disease monitoring, imatinib resistance, and use of novel, more potent tyrosine kinase inhibitors." | ( Baccarani, M; Cortes, J; Guilhot, F; Hochhaus, A; Kantarjian, HM; Lokey, L, 2007) |
| "The leukemic stem cells in patients with chronic myeloid leukemia (CML) are well known to be clinically resistant to conventional chemotherapy and may also be relatively resistant to BCR-ABL-targeted drugs." | ( Eaves, A; Eaves, C; Gasparetto, M; Jiang, X; Smith, C; Turhan, A; Zhao, Y, 2007) |
| "The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented." | ( Borthakur, G; Cortes, J; Faderl, S; Giles, F; Kantarjian, H; O'Brien, S; Ravandi, F; Rios, MB; Shan, J; Talpaz, M; Verstovsek, S, 2007) |
| "Treatment of maternal chronic myeloid leukemia with imatinib mesylate is avoided because of potential fetal effects." | ( Akhtar, MS; Carpenter, MW; Egorin, MJ; Lagattuta, TF; Russell, MA, 2007) |
| "Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine." | ( Cortes, JE; Giles, FJ; Jabbour, E; Kantarjian, HM; O'Brien, S, 2007) |
| "The majority of chronic phase chronic myeloid leukemia (CML) patients treated with the tyrosine kinase inhibitor (TKI) imatinib mesylate maintain durable responses to the drug." | ( Ambudkar, SV; Bates, SE; Boudriot, U; Brendel, C; Burchert, A; Dohse, M; Neubauer, A; Robey, RW; Scharenberg, C; Shukla, S; Wang, Y; Wennemuth, G, 2007) |
| "A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib, which has shown striking activity in the chronic phase and the accelerated phase, but less so in the blast phase of the disease." | ( Baran, Y; Gunduz, U; Ural, AU, 2007) |
| "We report 2 patients with chronic myeloid leukemia in the chronic phase showing diffusely increased F-18 fluorodeoxyglucose (FDG) uptake in the bone marrow before treatment." | ( Inoue, H; Jinnouchi, S; Kukita, T; Matsumoto, T; Nakajo, M; Otsuka, M; Tanabe, H; Tateno, R, 2007) |
| "In chemotherapy-treated patients with chronic myeloid leukemia (CML), the karyotypic detection of Philadelphia chromosome (Ph)-negative metaphases at diagnosis (i." | ( Dewald, GW; Ketterling, RP; Knudson, RA; Landstrom, AP; Tefferi, A, 2007) |
| "The treatment of chronic myeloid leukemia (CML) has considerably evolved since imatinib mesylate has been introduced as a new therapeutic weapon for this disease." | ( Hayette, S; Labussière, H; Michallet, M; Nicolini, FE; Tigaud, I, 2007) |
| "We report the first case of chronic myeloid leukemia (CML) in a patient with multiple sclerosis (MS) diagnosed within two years of receiving mitoxantrone therapy." | ( Rammal, M; Sadiq, SA; Sara, G, 2008) |
| "We compared immunologic parameters of chronic myeloid leukemia (CML) patients in cytogenetic remission receiving imatinib mesylate (STI) treatment, CML patients receiving interferon alpha (IFN-alpha), and healthy volunteers." | ( Iseki, T; Nagamura-Inoue, T; Nakayama, S; Ohno, N; Ooi, J; Takahashi, S; Tojo, A; Uchimaru, K; Yokoyama, K, 2007) |
| "Imatinib was the first treatment for chronic myeloid leukemia (CML) that specifically targeted the causative BCR-ABL oncoprotein, and represented a major therapeutic advance in this disease; however, some patients develop resistance or intolerance." | ( Kujawski, L; Talpaz, M, 2007) |
| "Imatinib is successfully used in the treatment of chronic myelogenous leukemia (CML), and the main mechanisms of resistance in refractory patients are now partially understood." | ( Auberger, P; Belhacene, N; Cassuto, JP; Colosetti, P; Grosso, S; Jacquel, A; Puissant, A, 2008) |
| "Imatinib, the treatment of choice for chronic myeloid leukemia, is generally well tolerated." | ( Assouline, S; Benemacher, V; Franceschino, A; Gambacorti-Passerini, C; Tornaghi, L, 2008) |
| "An association of Sweet syndrome with chronic myeloid leukemia (CML) has been recently observed in patients treated with tyrosine kinase inhibitors." | ( Baesecke, J; Baumgart, M; Emmert, S; Gesk, S; Ghadimi, BM; Glass, B; Haase, D; Kaune, KM; Mitteldorf, C; Neumann, C; Siebert, R, 2008) |
| "Over the past decade, the treatment of chronic myelogenous leukemia (CML) has gone through significant advances." | ( Bello, C; Pinilla-Ibarz, J, 2008) |
| "Treatment of chronic myeloid leukemia (CML) has changed drastically with the emergence of the Abl tyrosine kinase inhibitor (TKI), imatinib mesylate." | ( Kimura, S; Tanaka, R, 2008) |
| "We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy." | ( Burger, J; Cortes, J; Garcia-Manero, G; Jabbour, E; Jones, D; Kantarjian, HM; O'Brien, S; Reddy, N, 2008) |
| "We observed the excessive autophagy in chronic myelogenous leukemia (CML) cell line, K562, associated with treatment of 12-O-tetradecanoyl-phorbol-13-acetate (TPA), which can induce K562 cells to differentiate into megakaryocytic lineage." | ( Hatake, K; Kimura, S; Kuniyoshi, R; Mishima, Y; Ozawa, K; Takizawa, T; Taniyama, A; Terui, Y, 2008) |
| "We report here a very rare case of chronic myeloid leukemia (CML) following long-term chemotherapy with 5'-deoxy-5-fluorouridine (5'-DFUR) for gastric cancer." | ( Emi, N; Ezaki, K; Handa, K; Hasegawa, A; Maruyama, F; Mizuta, S; Okamoto, M; Tsuzuki, M; Watanabe, M; Yamamoto, K; Yamamoto, Y, 2008) |
| "We investigated chronic myelogenous leukemia (CML) patients who developed trisomy 8 abnormalities in Philadelphia-negative (Ph-) cells during imatinib mesylate treatment to evaluate the clinical outcome and laboratory features." | ( Cho, SG; Han, K; Jung, CK; Kim, CC; Kim, DW; Kim, M; Kim, Y; Lee, S; Lim, J; Min, WS, 2008) |
| "Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy." | ( Druker, BJ, 2008) |
| "The recent success in treating chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI), such as imatinib mesylate (IM), has created a demand for reproducible methods to accurately assess inhibition of BCR-ABL activity within CML cells, including rare stem and progenitor cells, either in vitro or in vivo." | ( Alhashimi, F; Hamilton, A; Holyoake, TL; Jorgensen, HG; Myssina, S, 2009) |
| "The drug is used for the treatment of chronic myeloid leukemia, malignant gastrointestinal stromal tumors, and some other conditions." | ( Pubalan, M; Wahiduzzaman, M, 2008) |
| "A patient with t(9;22)-positive chronic myelogenous leukemia (CML) developed a resistance to therapy with imatinib mesylate (Glivec) which coincided with the appearance of t(5;6;12) in the same cells with t(9;22) [46,XX,t(5;6;12)(q14?;q21?;q23?),t(9;22)(q34;q11)]." | ( Bogdanović, A; Denčić-Fekete, M; Gotić, M; Janković, G; Jovanović, J; Rocchi, M; Storlazzi, CT; Strnad, M; Todorić-Živanović, B; Đorđević, V, 2009) |
| "Although many patients with chronic myeloid leukemia (CML) respond well to imatinib therapy, a significant proportion loses their initial response." | ( Bleickardt, E; Borthakur, G; Chen, TT; Cortes, JE; Kantarjian, HM; Liu, D; O'Brien, S; Quintás-Cardama, A; Ravandi, F, 2009) |
| "Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients who are resistant to imatinib are commonly treated with second-generation tyrosine kinase inhibitors (TKIs)." | ( Alimena, G; Baccarani, M; Breccia, M; Castagnetti, F; Colaci, E; Foà, R; Iori, AP; Latagliata, R; Martinelli, G; Palandri, F; Rosti, G; Torelli, GF; Usai, S; Valle, V, 2010) |
| "A presumptive diagnosis of chronic myelogenous leukemia was made based on 3 factors: disease duration of greater than 3 months, a lack of identifiable foci of inflammation, and a lack of response to conventional therapy." | ( Messick, JB; Whittington, JK; Wiley, JL; Wilmes, CM, 2009) |
| "Imatinib is used to treat chronic myelogenous leukemia (CML), but resistance develops in all phases of this disease." | ( Auberger, P; Barbry, P; Cassuto, JP; Colosetti, P; Deckert, M; Dufies, M; Grosso, S; Jacquel, A; Lebrigand, K; Mari, B; Puissant, A, 2009) |
| "Here we report response to treatment of chronic myeloid leukemia (CML) of five pregnant women during and after pregnancy." | ( Cetkovský, P; Klamová, H; Machová Poláková, K; Marková, M; Moravcová, J; Sisková, M, 2009) |
| "We report on 8 chronic myeloid leukemia patients who developed serum lipase/amylase elevation during treatment with nilotinib." | ( Amabile, M; Baccarani, M; Castagnetti, F; Gugliotta, G; Luatti, S; Martinelli, G; Palandri, F; Poerio, A; Rosti, G; Soverini, S, 2009) |
| "For the minority of chronic myeloid leukemia (CML) patients who demonstrate primary or secondary resistance or intolerance to first-line imatinib therapy, previously available treatment options were limited to cytotoxic chemotherapy, interferon alfa, or allogeneic hematopoietic stem cell transplantation." | ( Giles, FJ, 2009) |
| "In imatinib-treated chronic myeloid leukemia (CML), secondary drug resistance is often caused by mutations in the BCR-ABL kinase domain (KD)." | ( Deininger, MW; Laudadio, J; Mauro, MJ; Press, RD; Willis, SG, 2009) |
| "PRAME mRNA expression increased with chronic myeloid leukemia (CML) disease progression and its detection in late chronic-phase CML patients before tyrosine kinase inhibitor therapy was associated with poorer therapeutic responses and ABL tyrosine kinase domain point mutations." | ( Abkowitz, JL; Cummings, CL; Epping, MT; Gooley, T; Guthrie, KA; Ladne, P; Oehler, VG; Pogosova-Agadjanyan, E; Radich, JP; Sabo, K; Shou, Y; Stirewalt, DL; Wood, BL; Yang, T, 2009) |
| "A subset of patients with chronic myeloid leukemia (CML) who receive imatinib therapy will require alternative therapy at some point owing to safety reasons or lack of efficacy." | ( Cortes, J; Kantarjian, H; Quintás-Cardama, A, 2009) |
| "Despite Imatinib's remarkable success in chronic myelogenous leukemia treatment, monotherapy frequently causes resistance, underlining the rationale for combination chemotherapy." | ( Calandra, G; Dillmann, F; Fruehauf, S; Laufs, S; Sperandio, M; Veldwijk, MR; Wenz, F; Zeller, J, 2009) |
| "In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008." | ( Alvares, LA; Azevedo, TC; Beltrão, AC; Bentes, AQ; Bentes, IR; Lemos, JA; Scerni, AC, 2009) |
| "We report on 48 chronic myeloid leukemia patients sequentially treated with 3 TKIs: 34 with dasatinib after imatinib/nilotinib failure and 14 with nilotinib after imatinib/dasatinib failure." | ( Cortes, J; Estrov, Z; Faderl, S; Garg, RJ; Kantarjian, H; O'Brien, S; Quintás-Cardama, A, 2009) |
| "First-line treatment for chronic myelogenous leukemia (CML) is imatinib, but some patients do not respond or develop resistance to the drug, leading to suboptimal responses." | ( Allen-Bard, S, 2009) |
| "For patients with chronic myeloid leukemia who become or are inherently resistant to imatinib therapy, including dose escalation, several important factors must be considered when deciding which strategy to attempt next." | ( Cortes, J; Hochhaus, A; Jabbour, E; Kantarjian, HM; La Rosée, P, 2010) |
| "The occurrence of chronic myeloid leukemia in pregnancy is rare and its management poses a clinical challenge for physicians treating these patients." | ( Bendit, I; Conchon, M; Dorliac-Llacer, PE; Sanabani, SS; Santos, FM; Serpa, M, 2009) |
| "We analyzed a cohort of 80 patients with chronic myeloid leukemia who were resistant to imatinib and who were treated with dasatinib or nilotinib while still in first chronic phase." | ( Apperley, JF; Bua, M; de Lavallade, H; Drummond, MW; Foroni, L; Goldman, JM; Holyoake, TL; Khorashad, JS; Marin, D; Milojkovic, D; Nicholson, E; Paliompeis, C; Reid, A; Rezvani, K; Shepherd, P; Szydlo, R, 2010) |
| "In chronic-phase chronic myeloid leukemia (CML) patients, the lack of a major cytogenetic response (< 36% Ph(+) metaphases) to imatinib within 12 months indicates failure and mandates a change of therapy." | ( Deininger, MW; Druker, BJ; Harrington, CA; Lange, T; Loriaux, MM; MacPartlin, M; McWeeney, SK; Melo, JV; O'Brien, SG; Pemberton, LC; Pillai, R; Snead, JL; Turpaz, Y; Vartanian, K; Willis, SG; Wilmot, B; Yochum, G, 2010) |
| "Patients with chronic myeloid leukemia (CML) who do not adhere to treatment may experience suboptimal outcomes." | ( Arana, M; Beaulieu, N; Bollu, V; Coombs, J; Cortes, J; Feng, W; Guo, A; Johnson, S; Wu, EQ, 2010) |
| "Imatinib is the leading compound to treat patients with chronic myelogenous leukemia (CML) but the exact mechanism of its anti-leukemic effect is incompletely elucidated." | ( Auberger, P; Cassuto, JP; Colosetti, P; Puissant, A; Raynaud, S; Robert, G, 2010) |
| "For adult patients who present with chronic myeloid leukemia (CML) in chronic phase it is now generally agreed that initial treatment should start with the tyrosine kinase inhibitor (TKI) imatinib at 400 mg daily." | ( Goldman, JM, 2009) |
| "Residual chronic myeloid leukemia disease following imatinib treatment has been attributed to the presence of quiescent leukemic stem cells intrinsically resistant to imatinib." | ( Apperley, J; Bonnet, D; Dazzi, F; Gomes, AR; Ho, KK; Lam, EW; Lymperi, S; Marin, D; Tisato, V; Vianello, F; Villanova, F, 2010) |
| "An elderly woman with chronic myeloid leukemia-chronic phase (CML-CP) aged at 67 underwent imatinib therapy." | ( Morioka, M; Saito, M, 2010) |
| "The lack of sensitivity of chronic myeloid leukemia (CML) stem cells to imatinib mesylate (IM) commonly leads to drug dose escalation or early disease relapses when therapy is stopped." | ( Cingolani, R; Coluccia, AM; de Luca, E; Di Renzo, N; Gambacorti-Passerini, C; Gigli, G; Leporatti, S; Maffia, M; Palamà, IE; Rinaldi, R, 2010) |
| "In a proportion of patients with chronic myeloid leukemia (CML) being treated with dasatinib, we recently observed large granular lymphocyte (LGL) expansions carrying clonal T-cell receptor (TCR) gamma/delta gene rearrangements." | ( Ekblom, M; Juvonen, V; Kairisto, V; Kreutzman, A; Mustjoki, S; Porkka, K; Seggewiss, R; Stenke, L, 2010) |
| "The treatment of chronic myeloid leukemia (CML) drastically changed with the introduction of imatinib mesylate, a Bcr-Abl1 tyrosine kinase inhibitor (TKI), in 1998." | ( Agrawal, M; Cortes, J; Garg, RJ; Quintás-Cardama, A, 2010) |
| "Imatinib has revolutionized the treatment of chronic myelogenous leukemia (CML)." | ( Cilloni, D; Fava, M; Gottardi, E; Saglio, G; Ulisciani, S, 2008) |
| "We found that imatinib treatment of chronic myeloid leukemia patients rapidly normalizes the characteristic miRNA expression profile, suggesting that miRNAs may serve as a novel clinically useful biomarker in this disease." | ( Bonnet, ML; Chomel, JC; Flamant, S; Guilhot, F; Guilhot, J; Holst, J; Rasko, JE; Ritchie, W; Turhan, AG, 2010) |
| "In the treatment of chronic myeloid leukemia (CML) with BCR-ABL kinase inhibitors, the T315I gatekeeper mutant has emerged as resistant to all currently approved agents." | ( Banda, G; Broudy, MI; Cai, L; Chen, I; Clackson, T; Commodore, L; Dalgarno, DC; Das, S; Huang, WS; Iuliucci, J; Keats, J; Lentini, SP; Liu, S; Metcalf, CA; Mohemmad, QK; Narasimhan, NI; Ning, Y; Qi, J; Rivera, VM; Romero, J; Russian, K; Sawyer, TK; Shakespeare, WC; Snodgrass, JT; Sundaramoorthi, R; Thomas, RM; Wang, F; Wang, Y; Wardwell, S; Wen, D; Xu, Q; Zhou, T; Zhu, X; Zou, D, 2010) |
| "Although imatinib is an effective treatment for chronic myelogenous leukemia (CML), and nearly all patients treated with imatinib attain some form of remission, imatinib does not completely eliminate leukemia." | ( Kim, PS; Lee, PP; Levy, D; Paquin, D, 2011) |
| "However, chronic myeloid leukemia (CML) is rarely complicated by the NS, and it occurs usually after allogenic stem cell transplantation or interferon alpha therapy for CML." | ( Kilara, N; Manjunath, R; Mysorekar, V; Subramanian, M, 2010) |
| "Around 40-50% of patients with chronic myeloid leukemia (CML) who achieve a stable complete molecular response (CMR; undetectable breakpoint cluster region-Abelson leukemia gene human homolog 1 (BCR-ABL1) mRNA) on imatinib can stop therapy and remain in CMR, at least for several years." | ( Arthur, C; Bartley, PA; Branford, S; Dang, P; Field, C; Filshie, RJ; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C, 2010) |
| "We examined our chronic myeloid leukemia patients treated with dasatinib at 100 mg or 50 mg daily and identified 4 of 13 patients who developed marked effusion formation." | ( Herndlhofer, S; Krauth, MT; Mitterbauer-Hohendanner, G; Schlögl, E; Schmook, MT; Valent, P, 2011) |
| "Patients with chronic myeloid leukemia who fail to achieve timely treatment responses have a worse prognosis." | ( Mustjoki, S; Porkka, K; Simonsson, B, 2009) |
| "We experienced a case of chronic myelogenous leukemia (CML) treated successfully with low-dose dasatinib (20 mg/day)." | ( Aota, Y; Gotoh, A; Sakurai, M; Takagi, Y, 2010) |
| "The median survival of patients with chronic myelogenous leukemia in myeloid blast crisis (MBC-CML) is poor even for patients treated with tyrosine kinase inhibitors (TKIs)." | ( Berthou, C; Castaigne, S; Cayuela, JM; Cony-Makhoul, P; Deau, B; Gardembas, M; Guerci, A; Guilhot, F; Guilhot, J; Guyotat, D; Hayette, S; Huguet, F; Legros, L; Mahon, FX; Michallet, M; Nicolini, FE; Pautas, C; Réa, D; Rousselot, P; Weiss, IR, 2011) |
| "The registration of one's own chronic myeloid leukemia (CML) patients in the TARGET system makes it possible to share experiences among physicians, and, thus, may facilitate appropriate treatment for patients." | ( Dan, K; Hino, M; Ikeda, Y; Inokuchi, K; Isobe, Y; Kizaki, M; Murayama, T; Ohyashiki, K; Okamoto, S; Oshimi, K; Saburi, Y; Shimomura, T; Tanaka, H; Tanimoto, M; Tauchi, T; Tsudo, M, 2011) |
| "In Cuba, chronic myeloid leukemia has been treated with interferon since 1998." | ( Baute, RG; Cabeza, AH; Cabrera, OM; Díaz, RM; Estrada, EE; Facundo, JC; Martínez, EE; Morán, VP; Núñez, AA; Otero, AG; Padrón, CH; Ramírez, PH; Sánchez, KL; Uría, JC; Virgil, AM, 2011) |
| "The outcome of treating chronic myeloid leukemia (CML) with imatinib mesylate (IM) is inferior when therapy is commenced in late chronic or accelerated phase as compared to early chronic phase." | ( Ang, CH; Bee, PC; Gan, GG; Liang, KL; Nadarajan, VS; Phan, CL; Zakaria, Z, 2011) |
| "Treatment of chronic-phase (CP) chronic myeloid leukemia (CML) with imatinib 400 mg/d can be unsatisfactory." | ( Balleisen, L; Gratwohl, A; Haferlach, C; Hänel, M; Hasford, J; Hehlmann, R; Hochhaus, A; Hossfeld, DK; Jung-Munkwitz, S; Krause, SW; Lauseker, M; Leitner, A; Müller, MC; Nerl, C; Pfirrmann, M; Pletsch, N; Pralle, H; Proetel, U; Saussele, S; Schlegelberger, B, 2011) |
| "Untreated chronic myeloid leukemia (CML) progresses from chronic phase to blastic crisis (BC)." | ( Acosta, JC; Albajar, M; Bermúdez, A; Delgado, MD; Donato, N; Gómez-Casares, MT; León, J; Llorca, J; Mauleon, I; Vaqué, JP, 2011) |
| "The majority of patients with chronic myeloid leukemia in early chronic phase (CML-ECP) who are treated with imatinib achieve a complete cytogenetic response with a significant reduction in the risk of progression to advanced phases." | ( Castagnetti, F; Dingli, D; Lenaerts, T; Pacheco, JM; Rosti, G; Traulsen, A, 2011) |
| "Imatinib mesylate is a first line treatment of Chronic Myelogenous Leukemia and of a rare form of gastrointestinal stromal cancer, where the response to the drug is also linked to the immune system activation with production of antineoplastic cytokines." | ( Catellani, S; Gobbi, M; Pierri, I; Poggi, A; Zocchi, MR, 2011) |
| "The outcome of chronic myeloid leukemia (CML) has been profoundly changed by the introduction of tyrosine kinase inhibitors into therapy, but the prognosis of patients with CML is still evaluated using prognostic scores developed in the chemotherapy and interferon era." | ( Baccarani, M; Guilhot, F; Guilhot, J; Hasford, J; Hehlmann, R; Hoffmann, V; Lindoerfer, D; Ossenkoppele, G; Pfirrmann, M; Porkka, K; Rosti, G; Saussele, S; Simonsson, B, 2011) |
| "The success of Imatinib (IM) therapy in chronic myeloid leukemia (CML) is compromised by the development of IM resistance and by a limited IM effect on hematopoietic stem cells." | ( Balabanov, S; Barett, C; Bokemeyer, C; Bosotti, R; Braig, M; Brümmendorf, TH; Gontarewicz, A; Holyoake, TL; Jost, E; Keller, G; Moll, J; Raddrizzani, L; Rohe, I, 2011) |
| "Treatment of chronic myeloid leukemia (CML) with the tyrosine kinase inhibitors (TKIs) imatinib mesylate and nilotinib represents a successful application of molecularly targeted anticancer therapy." | ( Branford, S; Cortes, J; Field, C; Gonen, M; Hughes, TP; Kantarjian, H; Michor, F; Quintas-Cardama, A; Tang, M, 2011) |
| "In imatinib-treated patients with chronic myeloid leukemia (CML), BCR-ABL mutations are the most common mechanism of resistance." | ( Bengió, RM; Bianchini, M; Bullorsky, E; Lanari, E; Larripa, I; Milone, J; Moiraghi, B; Murro, H; Riva, ME; Tezanos Pinto, Md; Ventriglia, V, 2011) |
| "About 20% of patients with chronic myeloid leukemia (CML) do not respond to treatment with imatinib either initially or because of acquired resistance." | ( Dinis, J; Fernandes, AR; Gromicho, M; Laires, A; Magalhães, M; Rodrigues, AS; Rueff, J; Tavares, P, 2011) |
| "In elderly patients with chronic myeloid leukemia treated with dasatinib, the rate of drug reduction or suspension and the incidence of pleural effusions seem to be associated with the presence of comorbidities: stratification according to the Charlson index and adult comorbidity evaluation-27 score before dasatinib therapy may enable the identification of patients at risk of major toxicities." | ( Abruzzese, E; Alimena, G; Annunziata, M; Breccia, M; Castagnetti, F; Cavazzini, F; Fava, C; Gozzini, A; Latagliata, R; Luciano, L; Pane, F; Pregno, P; Rege-Cambrin, G; Rosti, G; Russo Rossi, A; Santini, V; Sica, S; Specchia, G; Stagno, F; Vigneri, P, 2011) |
| "Patients with chronic myeloid leukemia, treated with imatinib, who have a durable complete molecular response, might remain in complete molecular response after stopping treatment." | ( Bartley, PA; Goyne, J; Grigg, AP; Morley, AA; Ross, DM; Seymour, JF, 2011) |
| "Although BCR-ABL+ stem cells in chronic myeloid leukemia (CML) resist elimination by targeted pharmacotherapy in most patients, immunological graft-versus-leukemia effects can cure the disease." | ( Altvater, B; Berdel, WE; Chen, CI; Gerss, J; Juergens, H; Kerstiens, L; Koschmieder, S; Lee, PP; Maecker, HT; Pscherer, S; Rossig, C; Schemionek, M, 2012) |
| "Targeted treatment of chronic myelogenous leukemia using imatinib has dramatically improved patient outcome." | ( Erben, P; Hanfstein, B; Härtel, N; Hochhaus, A; Klag, T; La Rosée, P; Mueller, MC; Schenk, T, 2012) |
| "Here, we report two chronic myelogenous leukemia patients; one had a suboptimal response according to European LeukemiaNet criteria (a major molecular response was not achieved after 18 months of standard-dose imatinib therapy) and the other had failure with a standard dose of imatinib." | ( Bendit, I; de Barros Ferreira, P; Dorlhiac-Llacer, PE; Martins, TF; Nardinelli, L; Sanabani, SS; Seguro, F; Serpa, M, 2012) |
| "The treatment of chronic myeloid leukemia (CML) was revolutionized by the introduction of the targeted tyrosine kinase inhibitor (TKI) imatinib mesylate." | ( Kalaycio, M; Tiu, R, 2012) |
| "Recent evidence suggests chronic myeloid leukemia (CML) stem cells are insensitive to kinase inhibitors and responsible for minimal residual disease in treated patients." | ( Allan, EK; Bhatia, R; Brunton, VG; Hamilton, A; Helgason, GV; Holyoake, TL; Koschmieder, S; Müller-Tidow, C; Myssina, S; Nicolini, FE; Schemionek, M; Zhang, B, 2012) |
| "Dasatinib has transformed the treatment of chronic myelogenous leukemia, resulting in durable remissions and prolonged survival." | ( Ahmed, SI; Al-akhrass, F; Rallapalli, V; Rodriguez, GH; Safdar, A, 2012) |
| "Outcomes in chronic myeloid leukemia have improved with tyrosine kinase inhibitor treatment." | ( Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W, 2012) |
| "We reviewed all 468 chronic myeloid leukemia patients treated at our institution with tyrosine kinase inhibitors as initial therapy: imatinib (n=281), nilotinib (n=98) or dasatinib (n=89)." | ( Cortes, J; Jabbour, E; Kantarjian, H; O'Brien, S; Pemmaraju, N; Quintas-Cardama, A; Ravandi, F; Shan, J; Verstovsek, S; Wierda, W, 2012) |
| "Molecular pathogenesis of chronic myeloid leukemia (CML) is well established and molecular monitoring for patients with CML has become an important practice in the management of patients on imatinib therapy." | ( Ainoon, O; Hamidah, NH; Hawa, AA; Leong, CF; Nurul, AN; Saw, F; Wong, FL, 2011) |
| "A major advancement in the treatment of chronic myeloid leukemia (CML) has been the development of imatinib and other BCR-ABL tyrosine kinase inhibitors." | ( Cao, L; Kang, R; Tang, D; Vernon, P; Yang, L; Yu, Y; Zhao, M; Zhu, S, 2012) |
| "Childhood chronic myelogenous leukemia (CML) is a rare malignancy, and experience with optimal treatment is very limited." | ( Eckardt, L; Millot, F; Suttorp, M; Tauer, JT, 2012) |
| "A series of 8 patients with chronic myeloid leukemia (CML) refractory to imatinib mesylate with no access to second-generation tyrosine kinase inhibitors were treated with hydralazine and valproate in a compassionate manner." | ( Candelaria, M; Cervera, E; Cortes, J; Dueñas-González, A; Gonzalez-Fierro, A; Gordillo-Bastidas, D; Labardini, J; López-Navarro, O; Taja-Chayeb, L, 2012) |
| "We have identified 5 patients with chronic myeloid leukemia (CML) in whom vascular events developed that were likely related to nilotinib therapy among 233 (2%) patients treated at our institution: 1 patient had recurrent Raynaud syndrome, a second patient had recurrent cerebrovascular accidents, and 3 other patients had PAOD (2 of them with other vascular events, including coronary artery disease and pulmonary emboli, respectively)." | ( Cortes, J; Kantarjian, H; Quintás-Cardama, A, 2012) |
| "We evaluated the outcomes of chronic myeloid leukemia (CML) patients receiving imatinib treatment in chronic (CP), accelerated (AP), and blast crisis (BP) phases." | ( Chen, S; He, H; Shen, Y; Zhu, Y, 2012) |
| "To investigate the clinical effect of chronic myelocytic leukemia (CML) patients treated with imatinib (IM) and interferon (IFN)-α." | ( Wu, SH; Xu, J; Zheng, CP, 2012) |
| "Over the last decade, the treatment of chronic myeloid leukemia has progressed tremendously." | ( Baccarani, M; Iacobucci, I; Martinelli, G; Rosti, G; Soverini, S, 2012) |
| "This is a case report of a patient with chronic myeloid leukemia (CML) undergoing imatinib treatment who became infected with dengue virus." | ( Chamnanchanunt, S; Iam-arunthai, K; Nakhakes, C; Suwanban, T; Thungthong, P, 2012) |
| "We report a 74-year-old female with chronic myelogenous leukemia (CML) in accelerated phase with pre-existing severe type 2 diabetes (T2D) and hemorrhagic gastric ulcers who was successfully treated with nilotinib." | ( Akashi, K; Chong, Y; Ito, Y; Kamimura, T; Maki, T; Miyamoto, T, 2013) |
| "We revised 182 chronic phase chronic myelogenous leukemia patients treated with frontline imatinib (IM) at two institutions from June 2002 to June 2011." | ( Alimena, G; Barulli, S; Breccia, M; Carmosino, I; Diverio, D; Federico, V; Finsinger, P; Isidori, A; Latagliata, R; Loglisci, G; Mancini, M; Nanni, M; Santopietro, M; Visani, G; Volpicelli, P; Vozella, F, 2013) |
| "Although the prognosis of chronic myeloid leukemia (CML) patients treated with imatinib is good, many fail to develop an optimal response or lose one." | ( Austin, G; Clark, RE; Davies, A; Foroni, L; Giannoudis, A; Holyoake, TL; Jorgensen, AL; Kottaridis, PD; Liloglou, T; Müller, MC; Pirmohamed, M; Pushpakom, S; Wang, L; Xinarianos, G; Zhang, JE, 2013) |
| "After more than a decade of treatment of chronic myeloid leukemia (CML) patients with the BCR-ABL tyrosine kinase inhibitor imatinib, and despite the impressive clinical results of this targeted therapeutic, many questions remain unresolved." | ( Mahon, FX, 2012) |
| "The frontline treatment for chronic myeloid leukemia (CML) is tyrosine kinase inhibitor therapy." | ( Bansal, D; Bhansali, A; Marwaha, RK; Narayanan, KR; Sachdeva, N; Varma, N; Walia, R, 2013) |
| "The tremendous progress made in chronic myeloid leukemia (CML) treatment affords patients more options than ever." | ( Simoneau, CA, 2013) |
| "Clinical evidence in chronic myeloid leukemia demonstrates a significant link between optimal response to tyrosine kinase inhibitor (TKI) therapy and favorable clinical outcome." | ( Jabbour, EJ; Quintás-Cardama, A, 2013) |
| "In patients with chronic myeloid leukemia, BCR-ABL mutations contribute to resistance to tyrosine kinase inhibitor therapy." | ( De Souza, C; Etienne, G; Fan, X; Hochhaus, A; Hoenekopp, A; Hughes, TP; Kalaycio, ME; Kantarjian, HM; Kim, DW; Kurokawa, M; Larson, RA; Rosti, G; Saglio, G; Shou, Y, 2013) |
| "We present a patient with chronic myelogenous leukemia who developed nephrotic-range proteinuria after initiation on dasatinib therapy that resolved after changing therapy to imatinib." | ( Chumley, P; Fatima, H; Jaimes, EA; Lyndon, W; Wallace, E, 2013) |
| "A 22-year-old male with Ph-positive chronic myelogenous leukemia (CML) was started on treatment with imatinib." | ( Hino, M; Koh, H; Koh, KR; Kosaka, S; Matsumoto, K; Morita, K; Nakamae, H; Nakane, T; Nishimoto, M; Ohsawa, M, 2013) |
| "A 33-year-old woman with chronic myelogenous leukemia developed widespread alopecia involving scalp and body hair within weeks after starting nilotinib therapy." | ( Hansen, T; Ioffreda, MD; Little, AJ; Miller, JJ, 2013) |
| "The present report describes two chronic myelogenous leukemia (CML) patients with the JAK2-V617F mutation who were in complete hematologic and cytogenetic remission and subsequently developed clinical features of essential thrombocythemia under treatment with tyrosine kinase inhibitors." | ( Han, SA; Lee, YJ; Moon, JH; Seo, JW; Seo, SK; Shin, HC; Sohn, SK, 2013) |
| "The success of imatinib therapy in chronic myeloid leukemia is highly influenced by its active transport into target cells." | ( Černelč, P; Kralj, E; Kristl, A; Marc, J; Ostanek, B; Pajič, T; Preložnik Zupan, I; Trontelj, J; Žakelj, S, 2013) |
| "A 45-year-old man with chronic myelogenous leukemia (CML) in the chronic phase was treated with imatinib mesylate (IM)." | ( Kataoka, T; Kayukawa, S; Kusumoto, S; Narita, T; Yoshida, T, 2013) |
| "Most patients with chronic myeloid leukemia (CML) treated with imatinib will relapse if treatment is withdrawn." | ( Arthur, C; Branford, S; Dang, P; Filshie, RJ; Goyne, JM; Grigg, AP; Hughes, TP; Melo, JV; Mills, AK; Ross, DM; Schwarer, AP; Seymour, JF; Slader, C; White, DL; Yeung, DT, 2013) |
| "Long-term treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) exerts off-target effects on bone growth by either impaired growth hormone (GH) action or osseous modelling impairment." | ( Glauche, I; Jung, R; Suttorp, M; Tabea Tauer, J; Ulmer, A, 2013) |
| "According to our findings, some chronic myeloid leukemia patients treated with imatinib may benefit from a switch to second-generation tyrosine kinase inhibitors (ClinicalTrials." | ( Aotsuka, N; Hata, T; Hatano, Y; Hino, M; Hirasawa, A; Itoh, K; Kashimura, M; Kuroki, J; Masuoka, H; Matsuura, Y; Miura, M; Miyazaki, Y; Mugitani, A; Nakagawa, Y; Nakamae, H; Nakane, T; Niioka, T; Nishiwaki, K; Sano, K; Sawada, K; Shinohara, Y; Takahara, S; Takahashi, N; Wakita, H, 2013) |
| "Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management." | ( Apperley, JF; Baccarani, M; Cervantes, F; Clark, RE; Cortes, JE; Deininger, MW; Goldman, JM; Guilhot, F; Hehlmann, R; Hjorth-Hansen, H; Hochhaus, A; Hughes, TP; Kantarjian, HM; Kim, DW; Larson, RA; Lipton, JH; Mahon, FX; Martinelli, G; Mayer, J; Müller, MC; Niederwieser, D; Pane, F; Radich, JP; Rosti, G; Rousselot, P; Saglio, G; Saußele, S; Schiffer, C; Silver, R; Simonsson, B; Soverini, S; Steegmann, JL, 2013) |
| "The molecular response of chronic myeloid leukemia (CML) patients to tyrosine kinase inhibitor treatment can be evaluated either by BCR-ABL mRNA levels on international scale (IS) or by log reduction from the baseline level of the laboratory." | ( Huang, XJ; Jiang, B; Jiang, H; Jiang, Q; Lai, YY; Li, JL; Li, LD; Liu, YR; Lu, XJ; Qin, YZ; Zhu, HH, 2013) |
| "In patients with chronic myeloid leukemia, high-quality diagnostics is of paramount importance for the surveillance of treatment efficacy." | ( Gastl, G; Kastner, U; Lion, T; Mitterbauer-Hohendanner, G; Seger, C; Webersinke, G, 2013) |
| "Progression and disease relapse of chronic myeloid leukemia (CML) depends on leukemia-initiating cells (LIC) that resist treatment." | ( Leser, U; Leutz, A; Rosenbauer, F; Scheller, M; Schönheit, J; Zimmermann, K, 2013) |
| "Molecular monitoring of chronic myeloid leukemia (CML) has been associated with improved clinical outcomes during tyrosine kinase inhibitor therapy (TKI), yet recent studies have demonstrated its use is far below published guidelines." | ( Chen, L; Dea, K; Goldberg, SL; Guérin, A; Wu, EQ, 2014) |
| "Treatment of chronic myeloid leukemia (CML) is challenging in patients who want to conceive." | ( Ali, Z; Aziz, Z; Iqbal, J; Khan, AU, 2014) |
| "Treatment of chronic myeloid leukemia (CML) has been drastically changed by the emergence of the ABL tyrosine kinase inhibitor (TKI), imatinib mesylate." | ( Ando, T; Kimura, S; Kojima, K, 2014) |
| "In patients with chronic myeloid leukemia (CML) in chronic phase who have achieved complete molecular remission on imatinib therapy, clinical trials from France and Australia have demonstrated that the majority experience prompt molecular relapse of their leukemia upon discontinuation of the drug, showing that long-term monotherapy with tyrosine kinase inhibitors is not curative in the majority of patients with CML." | ( Ahmed, W; Van Etten, RA, 2013) |
| "The first-line treatment in chronic myeloid leukemia (CML), imatinib, has been shown to decrease the production of amyloid-β (Aβ) in vitro and in animal studies." | ( Blennow, K; Guilhot, F; Legros, L; Livesey, FJ; Olsson, B; Smith, J; Strömberg, K; Wilson, DH; Zetterberg, H, 2014) |
| "Sustained imatinib treatment in chronic myeloid leukemia patients can result in complete molecular response allowing discontinuation without relapse." | ( Adiko, D; Bureau, C; Dulucq, S; Etienne, G; Etienne, M; Fort, MP; Hayette, S; Lippert, E; Mahon, FX; Marit, G; Morisset, S; Nicolini, FE; Reiffers, J; Schmitt, A; Tigaud, I, 2014) |
| "Imatinib is the frontline therapy for chronic myeloid leukemia (CML) management." | ( Digumarti, R; Gundeti, S; Jiwtani, S; Kagita, S; Linga, VG; Uppalapati, S, 2014) |
| "The treatment of chronic myeloid leukemia (CML) with BCR-ABL1 tyrosine kinase inhibitors (TKIs) is highly effective in reducing disease burden and prolonging overall survival in the majority of patients." | ( Lau, A; Seiter, K, 2014) |
| "Despite the use of targeted therapy, chronic myelogenous leukemia (CML) currently remains incurable with drug therapy, with patients requiring life-long treatment." | ( Jaymacker, J; Mowla, S; Njikan, S; Novitzky, N; Shankland, I; Shires, K, 2014) |
| "In this study, one in three chronic myeloid leukemia patients treated with a tyrosine kinase inhibitor were non-adherent to their regimen." | ( Anderson, KR; Chambers, CR; Cusano, F; Lam, N; Savoie, ML; Sheikh, N; Yau, PS, 2015) |
| "We recruited patients with chronic myeloid leukemia prescribed imatinib therapy and health professionals involved in their treatment from a specialized cancer center." | ( Butow, P; Chee, D; Schofield, P; Seymour, J; Ugalde, A; Wu, S, 2015) |
| "We reviewed 320 patients with chronic myeloid leukemia (CML) in chronic phase receiving Imatinib therapy with 3 and 6 month BCR/ABL transcript levels available, and divided them into four groups." | ( Hamad, N; Kamel-Reid, S; Kim, DD; Lee, HG; Lipton, JH, 2014) |
| "Standard care of chronic myeloid leukemia (CML) requires lifelong medication with oral therapy and regular follow-up." | ( Coleman, M, 2014) |
| "Dasatinib is an effective treatment for chronic myeloid leukemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)." | ( Hochhaus, A; Lindauer, M, 2014) |
| "The treatment of chronic myelogenous leukemia (CML) has been revolutionized by the introduction of tyrosine kinase inhibitors (TKI), however, with the exception of ponatinib, none of the existing licensed agents seem to eradicate the reservoir of Philadelphia positive stem cells, thus sustaining the disease over time, and retaining activity in cells and patients harboring an ABL T315I mutation." | ( Heiblig, M; Nicolini, FE; Sobh, M, 2014) |
| "The majority of chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) remain with residual disease." | ( Gladstone, DE; Gocke, C; Jones, RJ; Matsui, WH; Smith, BD; Zahurak, M; Zeidner, JF, 2014) |
| "The treatment of chronic myelogenous leukemia (CML) with specific tyrosine kinase inhibitors typically results in clinical success, although therapeutic failure frequently occurs." | ( Bera, S; Diamond, AM; Reinke, EN, 2015) |
| "A 23-year-old female with chronic myelogenous leukemia was treated with dasatinib at a dosage of 140 mg/d after failure of imatinib treatment and achieved complete cytogenetic response." | ( Liu, B; Mi, Y; Wang, J; Wang, Y, 2014) |
| "However, therapy-related chronic myelogenous leukemia is relatively rare." | ( Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M, 2014) |
| "Approximately 40% of patients with chronic myeloid leukemia (CML) receiving imatinib fail treatment." | ( Austin, G; Clark, RE; Davies, A; Foroni, L; Giannoudis, A; Holyoake, TL; Kottaridis, PD; Müller, MC; Pirmohamed, M; Wang, L; Zhang, JE, 2014) |
| "There were total 655 cases of chronic myeloid leukemia treated in one single-institution enrolled in this study." | ( Li, XL; Liu, HY; Liu, T; Lü, SJ; Niu, T; Wu, Y; Zheng, SP; Zhu, HL, 2014) |
| "In patients with chronic myeloid leukemia (CML) responsive to imatinib, it is still unknown whether the long-lasting treatment could induce the appearance of a persistent/late chronic anemia." | ( Alimena, G; Breccia, M; Carmosino, I; Finsinger, P; Latagliata, R; Molica, M; Montagna, C; Romano, A; Salaroli, A; Santopietro, M; Serrao, A; Volpicelli, P; Vozella, F; Zacheo, I, 2015) |
| "The initial treatment for chronic myeloid leukemia in chronic phase (CP-CML) represents a complex process, which includes a prompt and precise diagnosis, the choice among three available tyrosine kinase inhibitors (TKIs), and the initial management of care for these patients, which will protract over a very long period of time." | ( Gambacorti-Passerini, C; Piazza, R, 2015) |
| "The treatment of chronic myeloid leukemia (CML) has improved considerably since the introduction of the tyrosine kinase inhibitor (TKI) imatinib in 2001 and the approval of second-generation TKIs (dasatinib and nilotinib) beginning in 2006." | ( Henk, HJ; Shapiro, M; Whiteley, J; Woloj, M, 2015) |
| "Despite recent advances in the treatment of chronic myelogenous leukemia (CML), the development of drug resistance and minimal residual disease remain major challenges for the treatment of CML patients, thus highlighting the need to develop innovative new approaches to improve therapeutic outcome." | ( Dicato, M; Diederich, M; Grandjenette, C; Mack, F; Morceau, F; Schnekenburger, M; Werz, O; Wiechmann, K, 2015) |
| "Treatment of chronic myelogenous leukemia (CML) with the BCR-ABL tyrosine kinase inhibitor (TKI) imatinib significantly improves patient outcomes." | ( Aslan, JE; Druker, BJ; Gruber, A; Healy, LD; Loren, CP; McCarty, OJ; Nowak, MS; Rigg, RA, 2015) |
| "Correspondingly, long-term treatment of chronic myeloid leukemia (CML) patients with imatinib (400 mg/day) resulted in a marked decrease in MC." | ( Arock, M; Baumgartner, S; Beham-Schmid, C; Cerny-Reiterer, S; Hartmann, K; Herndlhofer, S; Hoermann, G; Linkesch, W; Mannhalter, C; Müllauer, L; Rabenhorst, A; Sill, H; Sperr, WR; Stefanzl, G; Valent, P, 2015) |
| "Two patients with chronic phase chronic myeloid leukemia (CML) were switched to dasatinib therapy because of hematological progress while receiving imatinib." | ( Bang, JH; Choi, SY; Hong, JH; Jang, EJ; Jeon, HR; Jung, HO; Kim, DW; Kim, SH; Lee, SE; Oh, YJ; Park, JE; Yi, JE; Youn, HJ, 2015) |
| "A 51-year-old man with chronic myeloid leukemia (CML) was treated with imatinib (IM)." | ( Akahane, D; Asano, M; Fujimoto, H; Gotoh, M; Ito, Y; Katagiri, S; Kitahara, T; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Saito, Y; Suguro, T; Tanaka, Y; Tauchi, T; Umezu, T; Yoshizawa, S, 2015) |
| "For patients with chronic myelogenous leukemia who fail first-line therapy, several factors should be considered for the decision of the next treatment option." | ( Eigendorff, E; Ernst, T; Hochhaus, A; La Rosée, P, 2015) |
| "Although imatinib mesylate (IM) in the treatment of chronic myelogenous leukemia (CML) remains the best example of successful targeted therapy, majority of patients with CML suffer its toxicity profile and develop chemoresistance to existing therapeutic agents." | ( Ahn, KS; Jung, SY; Kim, C; Kim, SH; Kim, WS; Lee, JH; Lee, SG; Shim, BS, 2015) |
| "Patients with chronic myeloid leukemia from the state of Piauí were treated in only one reference center." | ( Lorand-Metze, I; Metze, K; Rego, MN, 2015) |
| "Here, we report of a patient with chronic myelogenous leukemia in blast crisis and with pulmonary failure due to leukostasis who recovered after a combination therapy of leukapheresis and imatinib treatment." | ( Azuma, K; Hagihara, K; Horiuchi, M; Imaizumi, J; Itoi, J; Kanashima, H; Nakao, T; Ueda, H; Yamane, T; Yoshida, M, 2015) |
| "Clinical outcomes of patients with chronic myeloid leukemia (CML) treated in clinical trials, including response to therapy, may not be representative of those treated in a community setting." | ( Bhor, M; Bhowmik, D; Bolinder, B; Cain, Z; Di Bella, NJ; Jabbour, EJ; Middlebrook, B; Okoro, T; Patt, D; Rembert, D; Yap, M, 2015) |
| "Success of imatinib in chronic myeloid leukemia (CML) therapy has undoubtedly proved utility of signalling molecules as therapeutic targets." | ( Ingle, AD; Molli, PR; Naik, NR; Pradhan, MB, 2015) |
| "We evaluated 25 chronic myeloid leukemia patients who had been previously treated with imatinib and a second tyrosine kinase inhibitor." | ( Albuquerque, DM; Almeida, MH; De Souza, CA; Delamain, MT; Lorand-Metze, I; Miranda, EC; Oliveira-Duarte, G; Oliveira-Duarte, V; Pagnano, KB; Ribeiro, BF; Silveira, RA; Vergílio, B, 2015) |
| "We previously showed that incubation of chronic myeloid leukemia (CML) cells in very low oxygen selects a cell subset where the oncogenetic BCR/Abl protein is suppressed and which is thereby refractory to tyrosine kinase inhibitors used for CML therapy." | ( Ben-Califa, N; Cheloni, G; Cipolleschi, MG; Del Poggetto, E; Dello Sbarba, P; Gozzini, A; Kashman, Y; Marzi, I; Neumann, D; Rovida, E; Tanturli, M; Tusa, I, 2015) |
| "Ruxolitinib is a promising agent in chronic myeloid leukemia treatment by blocking JAK/STAT pathway known as downstream of BCR-ABL and triggering autophagy." | ( Avci, CB; Bagca, BG; Gunduz, C; Kurt, CC; Mutlu, Z; Ozalp, O; Saydam, G, 2016) |
| "Given the efficacy of dasatinib in the treatment of chronic myelogenous leukemia and our patient's mild symptoms of inclusion body myositis, he continued to receive dasatinib under close clinical and laboratory observation." | ( AlJohani, NI; Carette, S; Lipton, JH, 2015) |
| "We examined apoptosis of chronic myelogenous leukemia (CML) cells after treatment with 4-MU using annexin V/propidium iodide (V/PI) analysis and poly (ADP-ribose) polymerase (PARP) cleavage." | ( Ban, H; McKallip, RJ; Uchakina, O, 2015) |
| "In patients with chronic myeloid leukemia (CML), first-line imatinib treatment leads to 8-year overall survival (OS) probabilities above 80%." | ( Baccarani, M; Castagnetti, F; Cervantes, F; Guilhot, J; Hasford, J; Hehlmann, R; Hoffmann, VS; Ossenkoppele, G; Pfirrmann, M; Saussele, S; Simonsson, B, 2016) |
| "Treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) has significantly changed the survival of patients of all age categories." | ( Bělohlávková, P; Radocha, J; Voglová, J; Žák, P, 2015) |
| "Treatment options for chronic-phase chronic myelogenous leukemia (CML) based on medication-resistant mutations in BCR-ABL are reviewed." | ( Kolesar, JM; Kujak, C, 2016) |
| "Treatment of chronic myeloid leukemia (CML) has been profoundly improved by the introduction of tyrosine kinase inhibitors (TKIs)." | ( Baerlocher, GM; Brümmendorf, TH; Fabarius, A; Fauser, AA; Flasshove, M; Hanfstein, B; Hasford, J; Hehlmann, R; Heim, D; Hess, U; Hochhaus, A; Hofmann, WK; Hossfeld, DK; Kolb, HJ; Kraus, MP; Krause, SW; Lauseker, M; Mahlberg, R; Miranda, MB; Müller, MC; Neben, K; Nerl, C; Pfirrmann, M; Plöger, C; Proetel, U; Prümmer, O; Rendenbach, B; Saußele, S; Verbeek, W, 2016) |
| "The treatment of chronic myeloid leukemia (CML) has achieved impressive success since the development of the Bcr-Abl tyrosine kinase inhibitor, imatinib mesylate." | ( Choi, CW; Kang, MH; Kim, DS; Na, YJ; Yoon, SY, 2016) |
| "A 55-year-old male with chronic myelogenous leukemia was treated with dasatinib at a dosage of 100 mg/d." | ( Jin, J; Wang, C; Xu, XM, 2016) |
| "The prognosis for chronic myeloid leukemia, the first hematologic malignancy for which successful targeted therapy has been developed, has changed markedly in the West." | ( Belembaogo, E; Boguikouma, JB; Gaudong Mbethe, GL; Ibaba, J; Magne, C; Mounguengui, D; Moussavou Kombila, JB; Nzenze, JR; Ondounda, M; Yboutsi, L, 2016) |
| "Approximately 40% of chronic myeloid leukemia (CML) patients who discontinue imatinib (IM) therapy maintain undetectable minimal residual disease (UMRD) for more than one year (stopping IM (STOP-IM))." | ( Azuma, K; Fukuoka, Y; Katagiri, S; Kobayashi, C; Ohyashiki, JH; Ohyashiki, K; Okabe, S; Tauchi, T; Umezu, T, 2016) |
| "A 68-year-old man with a history of chronic myeloid leukemia was treated with imatinib." | ( Endo, Y; Ishida, M; Mekata, E; Minamiguchi, H; Ohta, H; Shimizu, T; Sonoda, H; Takebayashi, K; Tani, M; Tani, T, 2016) |
| "Experts from the Spanish Group of Chronic Myeloid Leukemia together with experts in cardiovascular risk have elaborated, after a consensus meeting, recommendations for the prevention and follow-up of CVE in patients with CML treated with TKI." | ( García-Gutiérrez, V; Gómez-Casares, MT; Jiménez-Velasco, A; López-Sendón, JL; Sánchez-Guijo, F; Steegmann Olmedillas, JL, 2016) |
| "Imatinib (IM) resistant Chronic Myeloid Leukemia (CML) is an important issue to be addressed while treating CML patients." | ( Du, QF; Li, R; Liu, XL; Xu, N; Zhang, JF, 2016) |
| "We present here a chronic myeloid leukemia patient harboring the T315I and E255V BCR-ABL1 mutation successfully achieved deep molecular response with a combined treatment of dasatinib and IFN-α." | ( Jiang, S; Liu, H; Ruan, C; Shi, H; Zhou, L, 2016) |
| "Therapy of chronic myeloid leukemia (CML) has been completely transformed by the development of tyrosine kinase inhibitors (TKIs)." | ( Assouline, SE; Damlaj, M; Lipton, JH, 2016) |
| "The treatment of chronic myeloid leukemia (CML), a clonal myeloproliferative disorder has improved recently, but most patients have not yet been cured." | ( Clarkson, B; Dokukin, ME; Guz, NV; Patel, SJ; Sokolov, I, 2016) |
| "We assessed patients with chronic myelogenous leukemia (CML) for serum calcium (Ca), phosphate (PO4), bone alkaline phosphatase, N-telopeptide (NTx), osteoprotegerin (OPG) levels, and trabecular bone area (TBA) in bone marrow (BM) specimens before and after treatment with dasatinib." | ( Bueso-Ramos, CE; Cortes, JE; Hidalgo, JE; Hoehn, D; Jabbour, EJ; Kanagal-Shamanna, R; Medeiros, LJ, 2016) |
| "Imatinib, which has revolutionized chronic myeloid leukemia (CML) treatment, was suggested to improve lipid profile." | ( Ashur-Fabian, O; Elis, A; Ellis, M; Gan, S; Hamburger-Avnery, O; Krashin, E, 2017) |
| "In patients with chronic myelogenous leukemia (CML), point mutations in the BCR-ABL1 kinase domain are the most common cause of treatment failure with a tyrosine kinase inhibitor (TKI)." | ( Albitar, M; Arcila, ME; Berman, E; Hedvat, C; Jhanwar, S; Levine, R; Ma, W; Maloy, M; Wahab, OA, 2016) |
| "BALB/c nude mouse model with huamanized chronic myeloid leukemia(CML) model has been established by pretreating mice with SLI." | ( Chen, WR; Huang, YH; Jia, WH; Li, DP; Liu, CC; Xu, YJ, 2016) |
| "Human chronic myeloid leukemia cells (K562), were treated with 20 μM of curcumin, and we found that a subpopulation of these cells were arrested and accumulate in the G2/M phase of the cell cycle." | ( Aleman-Lazarini, L; Bonilla-Moreno, R; Cedillo-Barron, L; Cordova, EJ; Martinez-Castillo, M; Meraz-Rios, MA; Orozco, L; Villegas-Sepulveda, N, 2016) |
| "To evaluate nationwide chronic myeloid leukemia (CML) treatment practices over an extended period and across multiple lines of tyrosine kinase inhibitor (TKI) therapy with imatinib, dasatinib, and nilotinib." | ( Bollinger, MJ; Frei, CR; Jones, X; Koeller, JM; Kreys, ED; Villarreal, SM, 2017) |
| "BACKGROUND Chronic myelogenous leukemia (CML) has unsatisfactory treatment efficacy at present." | ( Gong, J; Meng, J; Wang, Y; Zhang, L; Zheng, S, 2017) |
| "Pregnant women with chronic myeloid leukemia (CML) can be treated effectively with the tyrosine-kinase inhibitor imatinib, but data regarding fetal and neonatal exposure and safety are limited." | ( Brewer, D; Burwick, RM; Druker, BJ; Kuo, K, 2017) |
| "With high survival rates for chronic myeloid leukemia (CML) patients treated with BCR-ABL1 tyrosine kinase inhibitors (TKIs), emerging consequences, such as arterial ischemic events, require consideration when evaluating treatment options." | ( Cortes, J; Gooden, K; Kroog, G; le Coutre, P; Mahon, FX; Mayer, J; Rowlings, P; Saglio, G; Shah, NP; Subar, M, 2017) |
| "Drug resistance is an obstacle in the treatment of chronic myelogenous leukemia (CML), and is a common reason for treatment failure or disease progression." | ( Deng, Y; He, X; Yue, W, 2017) |
| "The majority of patients with chronic myeloid leukemia are successfully managed with life-long treatment with tyrosine kinase inhibitors." | ( Abruzzese, E; Albano, F; Baccarani, M; Bigazzi, C; Binotto, G; Bonifacio, M; Breccia, M; Caracciolo, C; Castagnetti, F; Cavazzini, F; Cavo, M; D'Adda, M; Foà, R; Gugliotta, G; Intermesoli, T; Iurlo, A; La Barba, G; Levato, L; Martinelli, G; Martino, B; Pane, F; Pregno, P; Rosti, G; Saglio, G; Sorà, F; Soverini, S; Stagno, F; Tiribelli, M, 2017) |
| "We report a case of a chronic myeloid leukemia patient showing progressive bone marrow fibrosis and anemia during imatinib therapy." | ( Bacci, F; Gentile, M; Greco, R; Lucia, E; Martino, B; Mauro, FR; Mendicino, F; Morabito, F; Morelli, R; Musolino, C; Recchia, AG; Sabattini, E; Vigna, E, 2017) |
| "All patients (N = 91) were adults with chronic myeloid leukemia treated with generic imatinib 400 mg/day." | ( Abbasi, S; Alrabi, K; Awidi, A; Kheirallah, KA, 2017) |
| "However, its effectiveness in treating chronic myeloid leukemia [corrected] remains unknown." | ( Cai, Z; Han, XY; He, JS; Pan, LL; Wu, WJ; Zheng, GF, 2017) |
| "Treatment of chronic myeloid leukemia (CML) with imatinib mesylate and other second- and/or third-generation c-Abl-specific tyrosine kinase inhibitors (TKIs) has substantially extended patient survival." | ( Baquero, P; Dunn, K; Gottlieb, E; Helgason, GV; Holyoake, TL; Kuntz, EM; Michie, AM; Tardito, S, 2017) |
| "A 69-year-old man was diagnosed with chronic myelogenous leukemia (CML) and treated with dasatinib." | ( Amaki, J; Ando, K; Kojima, M; Matsumoto, K; Miyaoka, M; Motoori, T; Nakamura, N; Numata, H, 2017) |
| "Methods Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated with low-dose imatinib (≤200 mg/day), but were resistant to this agent were enrolled in the current study (referred to as the LD-CML study)." | ( Hashino, S; Hino, M; Inokuchi, K; Iriyama, N; Kimura, S; Morita, S; Nakaseko, C; Ohashi, K; Sakamaki, H; Sakamoto, J; Takano, H; Uchiyama, M, 2018) |
| "Although imatinib is effective in chronic myeloid leukemia treatment, imatinib resistance due to the T315I mutation and/or other mutations is a challenge to be overcome." | ( Dong, Y; Gao, X; Liu, L; Wei, M; Xu, L; Yang, G; Zhao, Y, 2017) |
| "Here we present the case of a chronic myeloid leukemia patient with an inadequate response to imatinib due to concurrent phenytoin administration." | ( Díez, JL; Escudero-Vilaplana, V; García-González, X; Gómez-Centurión, I; González-Arias, E; Osorio, S, 2019) |
| "A 67-year-old white man with chronic myelogenous leukemia was treated with the dual Src and BCR-ABL tyrosine kinase inhibitor dasatinib." | ( Lejniece, S; Lejnieks, A; Lesina, K; Sablinskis, K; Sablinskis, M; Skride, A, 2017) |
| "Imatinib revolutionized the treatment of chronic myeloid leukemia (CML), but drug resistance and disease recurrence remain a challenge." | ( Du, X; Jin, Y; Li, J; Li, Y; Liu, C; Lu, Y; Nie, D; Pan, J; Zhou, J, 2018) |
| "It is unlikely that chronic myeloid leukemia arose as a result of clonal evolution secondary to fludarabine treatment given the very short interval after receiving fludarabine." | ( Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H, 2018) |
| "The treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKIs) has substantially extended patient survival." | ( Honma, Y; Ikejiri, F; Okada, T; Suzumiya, J; Urano, T, 2018) |
| "BCR-ABL1 is the hallmark of chronic myeloid leukemia (CML) in which treatment-free remission (TFR) is limited, with clinical and economic consequences." | ( Ahlert, H; Babor, F; Bhatia, S; Bopp, B; Borkhardt, A; Diedrich, D; Ernst, T; Frieg, B; Gohlke, H; Grez, M; Groth, G; Hansen, FK; Hauer, J; Hochhaus, A; Jose, J; Kassack, MU; Kögler, G; Krieg, A; Kröger, T; Kunkel, H; Kurz, T; Lang, F; Lüdeke, S; Marquardt, V; Nagel-Steger, L; Oldenburg, M; Opitz, FV; Remke, M; Rodrigues Moita, AJ; Stein, S; Zang, T, 2018) |
| "Therapies for the treatment of Chronic Myeloid Leukemia and other leukemias are still limited for patients at advanced stages, which allow development of point mutations in the BCR-ABL fusion gene that render CML cells insensitive to therapies." | ( Aliabadi, HM; Jiang, X; Manfrin, A; Mohseni, M; Uludag, H; Valencia-Serna, J, 2018) |
| "We report a high risk chronic myelogenous leukemia (CML) patient harboring the T315I mutation treated by Interferon-α (INF-α) solo and subsequently combined with dasatinib." | ( Li, X; Liu, J; Zeng, Y; Zhang, J; Zhang, L, 2018) |
| "Nonadherence is common in patients with chronic myeloid leukemia (CML) and leads to treatment failure and poor outcomes." | ( Chang, CS; Cho, SF; Hsiao, HH; Huang, WC; Lin, SF; Liu, TC; Liu, YC; Tsai, YF, 2018) |
| "A 52-year-old man with chronic myelogenous leukemia (CML) received dasatinib after the failure of imatinib and nilotinib therapy." | ( Aoki, N; Asakawa, K; Kikuchi, T; Koya, T; Moriyama, H; Okazuka, K; Oshima, Y; Sato, M; Watanabe, S, 2018) |
| "Cancer cells, including in chronic myeloid leukemia (CML), depend on the hypoxic response to persist in hosts and evade therapy." | ( Chan, ZE; Chuah, C; Lee, KL; Lee, LM; Majeed, A; Manjeri, A; Ng, KP; Ong, ST; Suda, T; Tan, CY; Tan, QD, 2018) |
| "Standard first-line therapy of chronic myeloid leukemia is treatment with imatinib." | ( Baerlocher, GM; Balleisen, L; Beelen, DW; Bentz, M; Berdel, WE; Bildat, S; Brossart, P; Brümmendorf, TH; Burchert, A; de Wit, M; Dengler, J; Eckart, MJ; Edinger, M; Fabarius, A; Falge, C; Fuchs, R; Gassmann, W; Geer, T; Goebeler, ME; Haferlach, C; Hahn, M; Hänel, M; Hasford, J; Hebart, H; Hehlmann, R; Heim, D; Hertenstein, B; Ho, A; Hochhaus, A; Hossfeld, DK; Kneba, M; Köhne, CH; Kolb, HJ; Krause, SW; Kremers, S; Lauseker, M; Lindemann, HW; Link, H; Mayer, J; Michel, C; Möhle, R; Müller, L; Nerl, C; Neubauer, A; Pfirrmann, M; Saussele, S; Schäfer, E; Schafhausen, P; Scheid, C; Schenk, M; Schlag, R; Schlegel, F; Schlegelberger, B; Spiekermann, K; Stegelmann, F; Thomalla, J; Trümper, L; Verbeek, W; Waller, CF; Wernli, M; Wündisch, T, 2019) |
| "A 49-year-old Chinese man with chronic myeloid leukemia received oral treatment with imatinib and initially exhibited a good response." | ( Huang, J; Jin, F; Ouyang, G; Pan, J; Zhang, P, 2019) |
| "A 40-year-old man with chronic myeloid leukemia was referred to our hospital because of proteinuria 1 month after dasatinib therapy was introduced." | ( Fujimoto, S; Fukuda, A; Minakawa, A; Ochiai, S; Sato, Y, 2019) |
| "Although treatment of chronic myeloid leukemia (CML) has improved with the development of tyrosine kinase inhibitors (TKIs), patients develop fatal blast crisis (BC) whilst receiving TKI treatment." | ( Fukuda, T; Kasama, T; Miura, O; Suwa, S; Uchida, E; Watanabe, K; Yoshimoto, R, 2019) |
| "To analyze the clinical features of chronic myeloid leukemia (CML) with T315 I mutation (CML-T315I) and compare the effectiveness of different treatments." | ( Cao, R; Chen, C; Huang, J; Jiang, X; Liao, L; Liu, L; Liu, Q; Liu, X; Wu, W; Xu, D; Xu, N; Yin, C; Zhang, Y; Zhou, X, 2019) |
| "We present the case of a 33-year-old chronic myeloid leukemia (CML) female patient, in whom the occurrence of nephrotic syndrome, during the treatment with tyrosine kinase activity inhibitors (TKIs), was potentially influenced by transient phenoconversion." | ( Arsov, B; Boban, L; Juginović, A; Mandac Rogulj, I; Matišić, V; Molnar, V; Primorac, D, 2019) |
| ": We aim to present a case of chronic myeloid leukemia (CML) in chronic phase, in major molecular response for 5 years of treatment with imatinib 400 mg OD." | ( Chauhan, R; Harankhedkar, S; Mahapatra, M; Nair, RR; Saxena, R, 2019) |
| "He had a history of chronic myeloid leukemia undergoing ipilimumab therapy." | ( Gonzales, JA; Tsui, E, 2020) |
| "A 53-year-old male was diagnosed with chronic myeloid leukemia and initiated imatinib mesylate as a treatment." | ( Bakanay, SM; Dilek, I; Kucuksahin, O; Maral, S, 2020) |
| "For instance, chronic myeloid leukemia is now well treated with imatinib, a tyrosine kinase inhibitor." | ( Dulucq, S; Etienne, G; Groppi, A; Hubert, C; Lichou, F; Longy, M; Mahon, FX; Monnereau, A; Orazio, S; Turcq, B, 2019) |
| "Treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute leukemia (Ph+ ALL) has been revolutionized with the advent of tyrosine kinase inhibitors (TKIs)." | ( Franke, GN; Goekbuget, N; Haverkamp, W; Jentsch-Ullrich, K; Junghanss, C; Kiani, A; Kirchmair, R; Koschmieder, S; La Rosée, P; Lang, F; le Coutre, P; Pfeifer, H; Rieger, C; Saussele, S; Stegelmann, F; Waller, CF, 2020) |
| "A 73-year-old woman with chronic myeloid leukemia developed severe pulmonary arterial hypertension (PAH) and pleural effusions after treatment with dasatinib." | ( Hirani, N; Orlikow, E; Weatherald, J, 2019) |
| "The treatment landscape of chronic myeloid leukemia (CML) was radically changed with the introduction of imatinib in 2001." | ( Alfraih, F; Chaudhri, N; El Fakih, R; Jabbour, E; Naqvi, K; Rausch, CR, 2020) |
| "We analyzed 120 samples from chronic myeloid leukemia patients in the chronic phase, who had been on imatinib treatment for at least 12 months." | ( Instiaty, I; Louisa, M; Nova, R; Priambodo, R; Rinaldi, I; Widyastuti, R, 2019) |
| "Approximately half of patients with chronic myeloid leukemia (CML) in sustained deep molecular response who discontinue tyrosine kinase inhibitors (TKIs) remain in treatment-free remission (TFR)." | ( Altamura, H; Braley, J; Branford, S; Carne, L; Dang, P; Grose, R; Hughes, TP; Kok, CH; McLean, J; Pagani, IS; Ross, DM; Rwodzi, Z; Saunders, VA; Shanmuganathan, N; Watts, S; White, DL; Yeung, DT; Yong, ASM, 2020) |
| "Treatment outcomes for chronic myeloid leukemia (CML) have dramatically improved with the development of tyrosine kinase inhibitors (TKI)." | ( Fujita, A; Igarashi, T; Inokuchi, K; Kozai, Y; Kumagai, T; Oba, K; Ohashi, K; Ohyashiki, K; Okamoto, S; Sakamaki, H; Sakamoto, J; Takezako, N; Wakita, H; Yamaguchi, H; Yamamoto, K; Yoshida, C, 2020) |
| "Thus, the patient was diagnosed with chronic myeloid leukemia (CML) in the chronic phase and tyrosine kinase inhibitor therapy with 100 mg of dasatinib daily was initiated." | ( Hirata, H; Io, K; Kitagawa, T; Nagai, K; Oka, T, 2020) |
| "Treating BCR-ABL-positive chronic myeloid leukemia remains impeded by the development of clinical resistance to imatinib." | ( Elf, SE, 2020) |
| "We recently treated a chronic myeloid leukemia (CML) patient with liver and renal dysfunction, who was undergoing hemodialysis (HD)." | ( Espinoza, JL; Hirase, C; Kumode, T; Matsumura, I; Miura, M; Morita, Y; Nakayama, S; Rai, S; Serizawa, K; Sueda, S; Takahashi, N; Tanaka, H; Taniguchi, Y; Watatani, Y, 2020) |
| "The treatment of chronic myeloid leukemia (CML) has been revolutionized by the advent of tyrosine kinase inhibitors." | ( Cherkaoui, S; Dakkoune, M; Hassoune, S; Khoubila, N; Lamchahab, M; Madani, A; Qachouh, M; Quessar, A; Rachid, M; Zoukal, S, 2020) |
| "However, the case of secondary chronic myeloid leukemia following acute myeloid leukemia treated with autologous hematopoietic stem cell transplantation is rare." | ( Bin, T; Chen, S; Chen, X; Cheng, J; Liao, Y; OUYang, J; Zou, W, 2020) |
| "Overall survival in chronic myeloid leukemia (CML) in chronic phase is not significantly different by treatment with first-line tyrosine kinase inhibitors (TKIs), but emerging evidence reveals differences in costs and safety profiles." | ( Cole, AL; Dusetzina, SB; Leech, AA; Nguyen, JT; Wood, WA, 2020) |
| "Taking as the starting point the Chronic Myeloid Leukemia (CML) optimal therapy model in [25], we design personalized optimal therapy models for patients with: CML; CML with intrinsic and/or induced resistance to the administered drug; CML and suffering high drug toxicity and/or allergy to the administered drug; and CML with presence of adverse factors." | ( Gutiérrez-Diez, PJ; Russo, J, 2020) |
| "The treatment of chronic myeloid leukemia (CML), a disease caused by t(9;22)(q34;q11) reciprocal translocation, has advanced largely through the use of targeted tyrosine kinase inhibitors (TKIs)." | ( Bai, J; Chen, X; Jiao, Y; Jing, H; Li, J; Liu, H; Wang, J; Wang, T; Weng, L; Yang, B; Ye, J; Zeng, YX; Zhang, W, 2020) |
| "A 61-year-old patient with chronic myeloid leukemia was treated with IM at 400 mg daily dose." | ( Charfi, M; Elloumi, M; Kallel, F; Kassar, O; Ksouda, K; Maaloul, I, 2021) |
| "Treatment-free survival (TFS) in chronic myeloid leukemia (CML) is a new goal." | ( Abdo, ANR; Bendit, I; Maciel, FVR; Nardinelli, L; Pereira, TDM; Rocha, V; Santos, FM; Seguro, FS, 2021) |
| "Patients with chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) were treated with ponatinib per current label." | ( Bailly, B; Beck, M; Bekaert, J; Benghiat, FS; De Becker, A; Deeren, D; Devos, T; Gadisseur, A; Granacher, N; Havelange, V; Janssen, M; Lewalle, P; Mazure, D; Meers, S; Selleslag, D; Theunissen, K; Triffet, A; Van Eygen, K; Vanstraelen, G; Vellemans, H; Vrelust, I, 2021) |
| "We present a case of a patient with chronic myelogenous leukemia (CML) treated with nilotinib who developed intracranial atherosclerosis leading to acute onset of stroke." | ( Jovin, TG; Kakadia, B; Sanborn, E; Suero-Abreu, GA; Thakkar, R; Then, R, 2021) |
| "Despite the successes achieved in chronic myeloid leukemia (CML) with tyrosine kinase inhibitor (TKI) therapy, resistance remains an obstacle." | ( Abubeker, A; Asres, G; Gebremedhin, A; Radich, J; Tadesse, F, 2021) |
| "He was diagnosed with chronic myeloid leukemia 13 years before and was treated with imatinib." | ( Himuro, N; Ito, K; Masutani, K; Miyake, K; Morita, N; Nakayama, T; Nawata, A; Ozaki, T; Sasaki, H; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T; Yokota, S, 2022) |
| "The current predictor of the Chronic myeloid leukemia (CML) patients' outcome is the degree of response to targeted therapy; here we search for a biomarker predicting CML outcome before start of therapy." | ( Abdel Hamid, M; Aref, S; Ayed, M; El-Sokkary, AMA; Fathy El-Metwaly, N, 2021) |
| "It is approved to treat of chronic myeloid leukemia (CML) in every phase of disease-resistant or intolerant to second-generation tyrosine kinase inhibitors (2GTKIs) and for whom imatinib is not clinically appropriate as well as for patients with T315I mutation." | ( Sacha, T; Szczepanek, E, 2021) |
| "Treatment of Chronic myeloid leukemia (CML) typically entails a long-term course of tyrosine kinase inhibitors (TKI) therapy." | ( Al Nahedh, M; Aljurf, M; Baqal, OJ; Binzaid, AA; Samarkandi, HH; Soheib, M, 2021) |
| "Nilotinib, a targeted treatment for chronic myeloid leukemia (CML), has been reported to be related with increased risk of adverse vascular events." | ( Chen, W; Du, B; Liu, K; Wang, X; Yang, P; Yu, Z, 2022) |
| "Patients with chronic myeloid leukemia in chronic phase (CP-CML) who are resistant or intolerant to second-generation tyrosine kinase inhibitors (TKIs) may benefit from treatment with a third-generation TKI, like ponatinib." | ( Haddad, FG; Issa, GC; Jabbour, E; Yilmaz, M, 2022) |
| "Imatinib is used to treat chronic myelogenous leukemia (CML)." | ( Abdelfattah, R; Hamza, MS; Moussa, HS; Omran, MM; Shouman, SA, 2022) |
| "Although chronic myeloid leukemia (CML) can be effectively treated using BCR‑ABL1 kinase inhibitors, resistance due to kinase alterations or to BCR‑ABL1 independent mechanisms remain a therapeutic challenge." | ( Ammerpohl, O; Böhm, R; Bruckmueller, H; Cascorbi, I; Kaehler, M; Kolarova, J; Litterst, M; Nagel, I, 2022) |
| "Despite advances in cancer treatment, chronic myeloid leukemia (CML) is still one of the leading causes of death in the world." | ( Naderbar, L; Pazhang, Y; Rezaie, J, 2022) |
| "The course of clinical management in chronic myeloid leukemia (CML) often faces a road-block in the form of front-line (imatinib) therapy resistance." | ( Acharjee, M; Basu, S; Bhattacharyya, D; Dey, S; Gupta, PP; Nath, S; Roychoudhury, S; Shah, S, 2022) |
| "The outcome for chronic phase (CP) chronic myelogenous leukemia (CML) patients has changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy." | ( Abdel Hammed, MR; Adam, EN; Ahmed, YA; Bakry, R; Elnaggar, MG, 2022) |
| "The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European Leukemia Net (ELN) criteria and adherence to ELN recommendations." | ( Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R, 2022) |
| "The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European Leukemia Net (ELN) criteria and adherence to ELN recommendations." | ( Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R, 2022) |
| "The real-world experience of Swiss chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) is largely unknown, in particular with regard to achievement of response per European Leukemia Net (ELN) criteria and adherence to ELN recommendations." | ( Balabanov, S; Cantoni, N; Kahn, S; Kulenkampff, E; Lambert, JF; Schmidt, A; Seitz, P; Sommavilla, R; Zenhaeusern, R, 2022) |
| "BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative malignancy generally treated with Dasatinib, a tyrosin-kinase inhibitor." | ( Bae, JY; D'Annunzio, S; Kelly, RL; Montanari, F, 2022) |
| "BACKGROUND Chronic myeloid leukemia (CML) is a myeloproliferative malignancy generally treated with Dasatinib, a tyrosin-kinase inhibitor." | ( Bae, JY; D'Annunzio, S; Kelly, RL; Montanari, F, 2022) |
| "The treatment of chronic myeloid leukemia (CML) is facing the dilemma of tyrosine kinase inhibitors (TKIs) resistance and disease recurrence." | ( Feng, W; Jiang, G; Peng, Y; Qin, Y; Wang, J; Yuan, Y; Zeng, F, 2022) |
| "The BCR::ABL1 gene fusion initiates chronic myeloid leukemia (CML); however, evidence has accumulated from studies of highly selected cohorts that variants in other cancer-related genes are associated with treatment failure." | ( Altamura, H; Braley, J; Branford, S; Feng, J; Grigg, AP; Hughes, TP; Kenyon, RR; King, RM; Kok, CH; Lin, M; Mills, AK; Pagani, IS; Ross, DM; Saunders, V; Schreiber, AW; Schwarer, AP; Scott, HS; Shahrin, N; Shanmuganathan, N; Thomson, D; Wadham, C; Wang, P; Yeung, DT; Yong, ASM, 2023) |
| "Though patients resemble phenotypically chronic myeloid leukemia, the treatment of patients with sole BCR-FGFR1 rearrangement are still challenging for clinicians due to rapid progressive nature and unavailability of uniform treatment guidelines." | ( Dhangar, S; Ghatanatti, J; Mathan S, LP; Sawant, L; Shah, A; Shanmukhaiah, C; Vundinti, BR, 2023) |
| "The outcome for chronic phase (CP) chronic myeloid leukemia (CML) patients was changed dramatically since the introduction of tyrosine kinase inhibitor (TKI) therapy." | ( Abd Elkader, AS; Abdel Hammed, MR; Mohamed, NM; Nafady, HA, 2023) |
| "Treatment with dasatinib for chronic myeloid leukemia (CML) has been associated with development of pleural effusion; however, data regarding its optimal management are limited." | ( Brokars, J; Chang, E; LeBlanc, TW; McBride, A; Reddy, SR; Tarbox, MH, 2023) |
| "Imatinib is highly effective in the treatment of chronic myelogenous leukemia (CML), but the primary and acquired imatinib resistance remains the big hurdle." | ( Bu, X; Ding, R; Feng, L; Li, M; Li, R; Li, Y; Qu, X; Ru, Y; Shen, L; Shen, T; Song, W; Wang, L; Wang, Y; Zhang, J; Zhang, P, 2023) |
| "The treatment of chronic myeloid leukemia (CML) was revolutionized with the advent of the first-generation tyrosine kinase inhibitors (TKIs), but drug resistance developed during treatment, leading to the development of the second-generation (dasatinib, nilotinib, and bosutinib) and third-generation (ponatinib) TKI." | ( Zhou, LY, 2023) |
| "The prognosis of chronic myeloid leukemia (CML) on tyrosine kinase inhibitor (TKI) treatment is based on the quantification of BCR::ABL1 fusion gene transcript copy number, harmonized by an international scale (IS) based on TaqMan-based real-time quantitative PCR (qRT-PCR)." | ( Abebe, M; Abeje, D; Alemayehu, D; Cross, M; Gebremedhin, A; Hailu, S; Howe, R; Jabessa, G; Kelemu, T; Kinde, S; Platzbecker, U; Seifu, D; Sherif, A; Tadesse, F; Tarekegn, A; Tsegaye, A, 2023) |
| "Patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) often experience cutaneous adverse events, such as rashes and pruritus." | ( Cha, SH; Kim, K; Song, YK, 2023) |